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ABSTRACT
This KwaZulu-Natal (KZN) based study investigates hypertension, glomerulonephritides
and the rarity of IgA Nephropathy (IgAN) in Africans in association with the Human
Leukocyte Antigen (HLA). A retrospective hypertensive study found a positive
association with HLA-B40 (P c<0.05) and HLA-B15 (Pc<0.02) in Indians and Africans
respectively. No association was found in Whites. A prospective study showed
glomerulonephritides to be positively associated with HLA-A33 in Indians (Pc 0.049).
No associations were found with glomerulonephritides in Africans and Whites.
Combined Race groups show no HLA associations. HLA-A30; HLA-A34; HLA-A29;
HLA-B42; HLA-B58; HLA-B70 and HLA-DR11 were extremely significantly higher in
Africans compared to Indians and Whites (all P<0.0001). In conclusion, HLA-B40 and
I 1LA-B15 are possible disease susceptibility markers in Indian and African
hypertensives; HLA-A33 is a possible disease susceptibility marker for
glomerulonephritides in Indians and alleles in linkage might be responsible for the rarity
of IgAN in Africans but further studies need to be employed.
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Glomerular Disease (GD) (Remuzzi et. al., 2006) and hypertension (Agnani et. al., 2005)
are the main contributors of end-stage renal disease (ESRD), requiring renal replacement
therapy which is very expensive and, unlike the United Kingdom (Ellis et. al., 1998), not
always guaranteed in South Africa. This is not feasible in a developing country like
South Africa where majority of the diseased renal population are poor but priority goes to
HIV/AIDS which is a social disease and tuberculosis.
Patients with delayed presentation of renal failure increase the numbers for renal
replacement therapy as pharmacological options are futile at this stage where ESRD is
inevitable (Ellis et. al., 1998). Kidney dysfunction is coupled with cardiovascular disease
(Ritz, 2006) hence disease of the kidney will ultimately lead to disease of the heart.
Certain genes of the immune system are said to be disease susceptibility genes whereas
certain genes are said to be protective (Mitchison et. al., 1996). This is a result of either
the disease susceptibility alleles being present in a higher proportion of patients when
compared to controls (in the case of disease susceptibility) or vice versa (in terms of
protection). The human major histocompatibility complex (HLA) is used to determine
possible disease susceptibility or protective alleles.  Carrying either a disease
susceptibility or protective allele will either predispose or initiate immunity to that
particular disease in an individual (Lipsitch et. al., 2003).
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Trowsdale (1995) described the major histocompatibility complex (MHC) as being the
`Centre of the Immune Universe' stimulating almost every immunological activity
involving cell-to-cell interaction (Kimball, 1986). Genes of the human MHC are present
on chromosome 6 and code for molecules that present processed antigens to cytotoxic T
cells.
HLA differs between race and geographic location (Kukko et. al., 2004). This is due to
polymorphic residues present in the peptide binding region of the HLA molecule.
Polymorphism is postulated to be a result of gene conversion and genetic drift (Parham
and Ohta, 1996), infectious disease outcome (Jeffery and Bangham, 2000) as well as
environmental factors (Kukko et. al., 2004). The MHC is extremely sensitive that even a
single amino acid substitution due to mutation can alter the antigen it presents (Mellins
et. al., 1988).
The aim of this study was to investigate associations between HLA and hypertension and
glomerular diseases in this diverse KZN setting. Although there is an immunological
genetic basis for each population responding differently to GD, a socio-economic racial
predisposition also exists (Seedat et. al., 1984).
IgAN has been found to be uncommon amongst the African race group (Jennette et. al.,
1985; Seedat et. al., 1984; Seedat et. al., 1988). No reason for this occurrence has been
found to date. It could be argued that the rarity of IgAN in Africans could be due to late
presentation with ESRD when diagnostic renal biopsies may not be available and this
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could be true in poor settings however, IgAN has also been shown to be rare in an
African American population (Jennette et. al., 1985). America is a first world, resource
rich country with a greater standard of health care. Therefore another goal of this study
was to attempt to find possible alleles present or absent in the HLA complex of the
African population that protects them against IgAN.
Associations have been found between HLA and the diseases under investigation in this
study in other settings (Freedman et. al., 1994a and b; Klouda et. al.. 1979; Kobayashi et.
al., 1985; Lagueruela et. al., 1990; Ruder et. al., 1990). In KZN, studies aiming to find
associations between HLA and nephrotic syndrome (NS) (Adhikari et. al., 1985) as well
as hepatitis B virus-associated membranous nephropathy (HBVMN) (Bhimma et. al.,
2002) have been carried out in the pediatric patient population. Significant associations
were found between the Class II HLA-DQB1*0603 and HBVMN in Black African
children, HLA-Bw44 in Indian and HLA-Bw21 in African children with NS.
HLA associations with HIV in KZN have suggested insight into vaccine design (Kiepiela
et.al., 2004). HLA studies may therefore provide the foundation on which other studies
are built upon towards the development of therapeutic measures.
With regards to HLA studies it is difficult to build upon earlier investigations as each
population (in terms of ethnicity as well as geographic location) has a unique HLA
profile although HLA-B 15 has been shown to be associated with hypertension in various
populations (Gudbrandsson et. al., 1980; Hilme et. al., 1993; Kristensen, 1981). It
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therefore becomes feasible to rather aim to prove similar associations or detect novel
disease susceptibility and protective alleles in populations where these studies have not
been carried out.
Another difficulty presented is the fact that the HLA type of a population is determined
by genetic recombination and environmental factors implying that each generation of the
same population in the same geographic area might have a different HLA profile. This
indicates that making use of information derived from HLA studies carried out in the past
may not at present be valid in the development of therapeutic measures as the HLA type
of a population is continually changing.
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About the Study
The HLA alleles under investigation in this study viz. HLA-A, -B and -DR were chosen
because they are they most polymorphic Class I and Class II HLA alleles. The
importance of studying the association of HLA with hypertension and renal diseases
stems from the fact that these are major contributors of ESRD. Detecting an allele that is
highly represented in the patient population is not sufficient to make any conclusions. It
is therefore important to compare the diseased individuals with healthy controls to
determine possible disease susceptibility or protective alleles which either predispose or
protect an individual from a particular disease. If a an allele is present in the diseased
population in amounts that greatly exceed the normal population and a significant
association is found after correcting the P value, that allele becomes a possible disease
susceptibility marker. This information can now be used as a basis for various other
studies including those towards the development of therapeutic measures.
This is primarily an aim driven study which is divided into three parts with distinct aims.
1. The first part of the study, Part A, aims to find associations (if any) of HLA
alleles with hypertension amongst the African, Indian and White populations in
KZN. In addition since HLA-B 15 has been shown to be associated with various
hypertensive populations, it was hypothesized that a similar association would be
found in KZN.
2. The second part of the study, Part B, aims to find associations between HLA
alleles and glomerulonephritides in KZN. These diseases include IgA
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nephropathy (IgAN), membranous glomerulonephritis (MGN) and focal
segmental glomerulosclerosis (FSGS). These diseases were chosen for the
following reasons. IgA nephropathy is the most prevalent primary
glomerulonephritides worldwide, FSGS is very common especially in African
males and MGN is known to be one of the most common causes of NS
3. The third part of the study, Part C, aims to investigate the reason for the rarity
IgAN in the African population by observing the genetic profile of the African
Race as a whole (combining diseased and normal populations) and comparing it




In order for the adaptive immune system to destroy a foreign antigen it first needs to
detect its presence (Turka, 1997). The body does not destroy its own antigens or that of
an identical twin (Jawetz et al., 1982) because they are recognized as "self' (except for
autoimmune disorders such as systemic lupus erythematosis) but when a foreign cell
enters the body by organ transplant (Wolfe, 1995) for example, its proteins are degraded
either cytosolically or endocytically and presented to the T Cell Receptors of T
lymphocytes bound to cell surface glycoproteins called the Major Histocompatibility
Complex proteins (Brodsky, 2001).
1.1 General Introduction of the Major Histocompatibility Complex
All nucleated (Barrett, 1988) vertebrate (Austyn and Wood, 1993) somatic (Hughes and
Yeager, 1998) cells have a set of molecules present on its surface which are responsible
for lymphocyte recognition (Schwartz, 1987) and antigen presentation (Brodsky, 2001;
Zacharias and Springer, 2004) termed The Major Histocompatibility Complex (MHC)
molecules. These molecules are polymorphic glycoproteins (Austyn and Wood, 1993)
which can be found in serum, saliva and urine (Braun, 1979) and are encoded by a
closely linked set of genes (Sayegh et al., 2000) that form a "complex" on chromosomes
called the MHC. The human MHC is present on the short arm of chromosome 6
(Williams, 2001), the rat MHC on chromosome 20 and the mouse MHC on chromosome
17 (Barrett, 1988; Margulies, 1999). The molecules of the MHC include the highly
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polymorphic class I and class II molecules (Pattison et al., 1997; Rees, 1997) and "the not
so polymorphic" class III molecules (Rees, 1997). Class I and class II molecules arc
specialized membrane proteins that facilitate T cells to recognize antigen (Austyn and
Wood, 1993) thus playing a vital role in graft rejection.
MHC was christened as such due to its discovery during initial transplant studies (Gorer,
1936a, b) and was acknowledged as an important ("Major") set of genes ("Complex")
which predispose the regulation of the acceptance of grafts between individuals whose
tissues are genetically similar ("Histcompatible") or rejected by individuals that are not
("Histoincompatible") (Austyn and Wood, 1993). In addition, minor histocompatibility
antigens which arc derived from polymorphic cellular proteins (Simpson et. at., 2002) do
not mount a rapid rejection response as MHC but play a role in tissue compatibility
( Austyn and Wood, 1993).
Discovery of the MHC antigens initially occurred during tumour transplant studies
between different strains of inbred mice (Gorer, 1936b) and were thus characterized as
transplant antigens (Hoecker, 1986). MHC antigens are the strongest and most important
transplant antigens as they provide the strongest incompatibilities for any type of tissue
and organ transplant in both animals and humans and are able to stimulate a primary
immune response without being sensitized (Sayegh et al., 2000). Other transplant
antigens include the minor histocompatibility antigens, ABO blood group antigens and
monocyte/endothelial cell antigens (Sayegh et al., 2000).
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Inbred strains, unlike outbred populations (e.g. humans) which are made up of a great
number of MHC haplotypes (Heise, 1984), are composed of genetically identical
individuals hence tissue transplantation between the same inbred strain was possible
without risk of rejection (Gorer, 1936a). Thus the tissues of one inbred strain are deemed
histocompatible in relation to each other but histoincompatible with another inbred strain
(Austyn and Wood, 1993).
In 1958, Dausset discovered agglutinating antibodies as a result from a reaction between
the sera of multi-transfused individuals as well as that of multiparous women and
leukocytes from blood donors. These serological studies demonstrated that agglutination
does not occur between the sera and leukocytes of the same individual or between those
of individuals who produce similar antibodies. It also demonstrated that leukocyte
antigens are genetically determined by Dausset's observation that the pattern of
agglutination from a series of antisera was identical in monozygotic twins but not in
dizygotic twins.
1.1.1 General features of the Major Histocompatibility Complex
Three different families of glycoproteins are coded for by the MHC viz. Class I, class II
and class III molecules (Austyn and Wood, 1993). Co dominant expression (Buckley,
2003), polygenicity and polymorphism are prominent features of the MHC (Janeway et.
al., 2005) which work together to prevent pathogens from invading the host cell. Class
and class II molecules are alloantigens which are expressed on the cell surface as
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membranous glycoproteins (Austyn and Wood, 1993). Class III molecules are soluble
proteins which include soluble effector molecules (Austyn and Wood, 1993) such as
enzyme steroid 21-hydroxylase (Hauptmann and Bahram, 2004), heat shock proteins
HSP70 (Porto et. al., 2005) and components of the complement system (Barrett, 1998).
The genes of the MHC are most common, divergent, evenly distributed (Parham and
Tomoko, 1996) and are highly polymorphic (Turka, 1997). In fact they are known to be
the most polymorphic cluster of genes that exist in the mammalian genome (Just, 1995;
Wooley and David, 1984).
Class I and Class II molecules are involved in antigen processing and presentation of
peptides within the cell or those from extracellular space (Stevanovia, 2002) via the
cytosolic and endocytic pathways respectively (Brodsky, 2001).
1.1.2 Nomenclature
MHC nomenclature is extremely complicated due to the presence of different
nomenclature systems between species and not as a result of any fundamental distinctions
between the structure and function of the MHC molecules (Austyn and Wood, 1993).
Due to the rapid increase of new alleles (Braun, 1979) and novel findings (Margulies,
1999) further complications are discovered bringing about a need for greater precision
from historical systems (Margulies, 1999).
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1.1.2.1 Nomenclature in terms of species
MHC in the mouse is designated H-2 (Panayi and David, 1984) and is maintained for
historical reasons as it was the second of the four blood group antigens that Gorer
discovered to have an association with tumour transplants. Except for B used to describe
the chicken MHC (GOtze, 1981) and RTI, which replaces the old nomenclature AgB used
to describe the rat MHC, most of the nomenclature systems were designed around that
assigned to humans — HLA which represents human leukocyte antigen or more
specifically human leukocyte associated antigen A (Austyn and Wood, 1993). Hence
ChLA is used to describe the chimpanzee leukocyte antigen (Margulies, 1999); RLA, the
rabbit leukocyte antigen (Austyn and Wood, 1993); BoLA, the cattle (bovine) leukocyte
antigen (GOtze, 1981) DLA, the dog leukocyte antigen (Margulies, 1999); GPLA, the
guinea pig leukocyte antigen (Austyn and Wood, 1993); SLA, the swine (pig) leukocyte
antigen (Margulies, 1999) and RhLA, the rhesus monkey leukocyte antigen (van Rood et
c.d., 1981).
1.1.2.2 Nomenclature in terms of the gene map
The earliest genes of the MHC that were recognized are classified as MHC genes because
the cell surface molecules they encode can be detected by antibodies and transplantation
responses (Margulies, 1999). At present there are hundreds of mouse and human MHC
genes but MHC molecules refer distinctively to MHC-I and MHC-11 structurally and
functionally related molecules (Margulies, 1999).
As of April 2007, the international ImMunoGeneTics (IMGT) Database currently
contains 545 Class I HLA-A alleles, 894 Class I HLA-B alleles, 307 Class I HLA-C
alleles, 3 Class II HLA-DRA alleles, 577 Class II HLA-DRB alleles, 34 Class II HLA-
DQA1 alleles, 83 Class II HLA-DQB1 alleles, 23 Class II HLA-DPA1 alleles and 126
Class II DPB1 alleles.
Specific MHC genes are denoted by a letter for the locus after the prefix e.g., for the
mouse MHC, H-2K where H-2 is the prefix and K is the locus (Margulies, 1999). An
example of the human MHC is HLA-A where HLA is the prefix and A is the locus
(Margulies, 1999).
Alleles of the mouse MHC have been designated by adding a subscript to the locus for
e.g., H-2Kb and H-2Kd where Kb and Kd are two different alleles present at the same locus
(Margulies, 1999). Human MHC class II genes are designated HLA-D but murine MHC
class II genes are denoted as H-2IAa, H-2IAb, H-2IEa, H-2IEb where a and b
respectively denote the alpha (a) and beta ((3) coding chains (Margulies, 1999).
The nomenclature system for the human MHC is developed by the HLA Nomenclature
Committee of the World Health Organization (WHO) (Schwartz, 1987). The classical
HLA MHC class I genes officially recognized by the WHO are HLA-A, HLA-B and
HLA-C (Schwartz, 1987) and the MHC class II region is HLA-D which comprises HLA-
DR, HLA-DP and HLA-DQ loci (Austyn and Wood, 1993). Non classical MHC genes
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with limited immune functions and a low degree of polymorphism and expression are the
MHC-Ib genes viz. HLA-E, HLA-F and HLA-G (Williams, 2001).
Provisionally accepted antigens have a "w" placed between the locus and the number e.g.,
HLA-Bw22 (Braun, 1979) and is a result of inaccurate serological assignments
(Margulies, 1999). When it becomes officially recognized and accepted the 'w', which
stands for workshop, is eliminated (Schwartz, 1987) and the allele becomes HLA-B22.
MHC Class I loci only encompass a single gene (Austyn and Wood, 1993) whereas the
Class II region contains the A and B genes which may confer antigen variability
(Williams, 2001) e.g., HLA-DRA and HLA-DRB1 (Austyn and Wood, 1993).
The Human MHC is known to be the predominantly investigated (Janer and Geraghty,
1998) and most polymorphic set of genes present in the human genome (Jeffery and
Bangham, 2000; McCluskey and Peh, 1999) and initial serological methods used to
resolve alleles proved to be inadequate in detecting the variation of the alleles that
antibodies were unable to gain access to thus bringing about a need for modern molecular
methods (McCluskey and Peh, 1999). For example alleles identified by serology is
denoted as HLA-A2 and those identified by DNA typing, HLA-A * 0201.
In order to fully understand the way the human designation works, a conversion table
(Table 1.1.1 and Table 1.1.2) which aligns the alleles that have been resolved
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serologically with those that have been resolved by modern DNA typing methods needs
to be consulted (Margulies, 1999).
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Table 1.1.1 Classical HLA Class I Alleles and their Serological Designations.










Al A*0101-A*0125 87 8*0702 -B*0755 Cwl Cw*0102-Cw*0118
A2 A*020I-A*0299 88 13*0801-B*0833 Cwt Cw . 0202-Cw*02 I 8
A3 A*0301-A*0329 813 13*1301-8*1318 Cw3 Cw•0302-Cw*0340
All A*110I-A*1130 B14 8*I401 -B*1407 Cw4 Cw*0401-Cw*0427
A23 A*2301-A*2315 B15 B*1501 -B*1599 Cw5 Cw*0501-Cw*0516
A24 A*2402-A•2476 B18 B*180I-B*1826 Cw6 Cw . 0602-Cw*O6 ION
A25 A*2501-A*2506 B27 8*2701-8*2737 Cw7 Cw*0701-Cw*0748
A26 A*260 I -A*2534 B35 B*3501-B*3557 Cw8 Cw*080 I -Cw*0814
A29 A*2901-A*2916 B37 B*370143 . 3713 Cw12 Cw*1202-Cw*1221
A30 A . 3001-A.3021 1338 13.3801-B*3816 Cw I 4 Cw.1402-Cw. I 408
A31 A*3101-A*3117 B39 8*390I -B*394 I Cwl 5 Cw*1502-Cw*1520
A32 A*3201-A*3215 1340 8*4001-13 . 4075 Cwl 6 Cw* I 601-Cw*I609
A33 A*3301-A*3310 B41 13*4101-8 . 4108 Cwl 7 Cw*1701-Cw*1704
A34 A. 3401 -A*3408 B42 B.4201 -B .4209 Cw 1 8 Cw. 180 I -Cw.I803
A36 A*3601 -A*3604 1344 B*4402-B*4453
A43 A*4301 1345 8*4501 -B*4507
A66 A*6001 -A*6606 B46 8*4601-8*4610
A68 A. 6801 -A.6838 847 B . 4701 -B .4705
A69 A*6901 B48 B*4801-8*4816
A74 A*7401 -A*7412 1349 8*4901 -B*4905
A80 A*8001 B50 B*500143 . 5004















1395 B . 950 I -B.9529
Adapted from httn://www.anthonynolan.org.uk/HIG/lists/classllist.html
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Table 1.1.2 Classical HLA Class II Alleles and their Serological Designations.
DRA DRA*010 I -DRA*0202 DQAI DQA I *0101-DQAI*0107 DPAI DPA1*0103-DPA*0109
DQA I *0201 DPA I *020I-DPA*0203
DRB1 DRBI*0101-DRBI*0116 DQAI*0301-13QA1 . 0303 DPA1*0301-DPA*0303
DRI31 . 0301-DRBI*0335 DQAI *040 I -DQA I *0404 DPAI *0401
DRBI*0401-DRB1*0464 DQA1 .0501-DQA1*0509
DRB1*0701-DRBI *0712 DQA1*0601-DQAI*0602 DPB I DPB1 . 0101-DPB1.0102
ORB 1 *0801-DRB1*0832 DPB1*0201-DPB1.0203
ORB 1 .0901-DR B I *0906 DQB I DQB I *0201-DQBI*0205 DPB I *0301-DPLII *0302
DREII*100101-DRBI*100103 DQB I *030 I -DQB I *0320 DP131*0401-DPB1*0403
DRBI *11101-DRB I *1163 DQB1*0401-DQB I *0402 00131•0501-DPB I *0502
ORBI*1201-DRBI*1215 DQB I *050 I - WEI I *0505 DP B I *0001 -DI'B1*0602
DR BI *1301-DRB1 * 1375 DQB1*0601-DQ131*0630 DI'B I *0001 -DI'B I *0802
DRBI*1401-DRBI*1466 DPBI*090 I -DP B I *0902
DRBI *150I-DRBI*1522 DPB1 . 1 001-DPB1•1002
DRBI*1601-DR/31 . 1611 DPBI*1101-DPBI*1102
DPB1.1301-DP131 . 1302
DRB2 DRB2*0101 DPB1 . 1 401-DPB1 . 1402
DPB1 . 1501-DPB1*1502
DRB3 DRB3*0101-DRB3*0111 DPBI *1601 -DPB1*1602
DRB3*0201-DRB3*0222 DPB I *1701-DPBI*1702
DRE3*0301-DRB3.0303 DRBI*1801-DPB1*1 802
DPBI*1901-DPB1.1902
DRB4 DRB4*0101-DRB4•0107 DPBI *2001-DPBI *2002
DR134*0201N DPB1*2101 -DPBI *2901
DRB4*030 IN DPB I • 3001-DPBI *3901
01 131 . 4001 -DP13 I *4901
ORBS DRB5*0101-DR135*0113 DPI31*5001-DPB1*5991
DRB5 •0202-DRB5*0205 DI131 . 6001-DPB I *6901
DPB1*7001-DPBI *7901
DRB6 DRB6*0101 DIIB I *8001-DPBI*8901
DRI36 .0201-DRB6*0202 DPB1 . 9001-DPB1*9901





In the human MIIC, alleles are denoted by adding a letter and a number e.g., HLA-A2
where 2 is the allele at locus A (Margulies, 1999). Human MHC genes can be more
specifically denoted by adding a superscripted asterisk (McCluskey and Peh, 1999) to the
prefix-locus combination followed by a four digit number (Margulies, 1999) to the locus
which corresponds to a specific allele e.g., HLA-A *0201 (McCluskey and Peh, 1999).
The first two digits following the locus represent the fundamental serological specificity
of the allele and the following two a specific allele sequence but the addition of a fifth
digit indicates a silent polymorphism (Leffell, 2002; Williams, 2001). Variations that
take place outside the coding region result in the addition of a sixth and seventh digit
( Williams, 2001). The presence of a null allele sequence is denoted by the addition of an
N to the allele number (Williams, 2001). A simplified illustration can be seen by Table
1.1.3.
Private antigens are HLA antigens which are resolved by a single allele alone as opposed
to public antigens which are familiar to a number of HLA molecules and which bears its
own private antigen (Schwartz, 1987). Excellent examples of HLA public antigens are
HLA-Bw4 and HLA-Bw6 (Schwartz, 1987). HLA antigens that were originally
considered to be single private antigens were identified as being part of a group of 2 to 3
closely related antigens, each of narrow specificity and characterized as 'splits' of the
original antigen of broad specificity (Schwartz, 1987).
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Nomenclature of split antigens occurs as follows. The broad antigen of which the split is
made follows the split in parenthesis (Schwartz, 1987) for example, HLA-DR15(2) and
HLA-DR16(2) implies that both HLA-DR15 and HLA-DR16 are splits of the broad
antigen HLA-DR2 (Margulies, 1999) indicating that HLA-DR2 could possibly be
regarded as a public HLA antigen which bears HLA-DR15 and HLA-DR16 as private
antigens (Schwartz, 1987).
Blank alleles are indicative of homozygous alleles or alleles that cannot be defined by the
available reagents (Schwartz, 1987). This could be due to the great polymorphism of the
MHC whereby reagents produced in one country for a certain allele may not be able to
detect alleles of an entirely different population. Blank alleles present with resolved
alleles may be defined by family studies (Schwartz, 1987).
Table 1.1.3 A Simplification of HLA Nomenclature.
HLA Designation Indicative of
HLA Human MHC (Human Leukocyte Antigen)
HLA-A The A locus at Human MHC




HLA-A*0201101 Variation outside the coding region
HLA-A*0201101N Null allele outside the coding region
* Adapted from McCluskey and Peh, 1999.
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1.1.3 Inheritance of MHC In Humans
Humans inherit their HLA genes by a Mendelian-dominant method (Buckley, 2003;
Sayegh et. al., 2000; Sullivan and Amos, 1986). Inheriting a specific combination of the
six MHC loci (viz. Class I and Class II) is referred to as a haplotype (Brodsky, 2001)
which is passed on to the offspring by one of the parents (Payne, 1977) due to linkage of
the HLA genes and low crossover rates (Buckley, 2003; Sayegh et. al., 2000). Each
individual has two haplotypes each inherited from one parent (Buckley, 2003; Sullivan
and Amos, 1986) thus constituting the genotype (Payne, 1977).
1.1.4 Structure of The Human Major Histocompatibility Complex
1.1.4.1 Gene Structure of Human MHC (HLA)
The genes which encode the HLA are present on the short arm of autosome (Buckley,
2003) chromosome 6 (Williams, 2001) in the distal portion (Rees, 1997) of the 6p21.3
(Alper et. al., 2006; Rees, 1997) band between 6p21.31 and 6p21.32 (Margulies, 1999).
The HLA complex comprises more than 200 genes, extends over 4 x 10 6 nucleotides
(Janeway et. al., 2005) inhabiting a segment of about 4 centimorgans (cM) (Schwartz,
1987) and forms a linkage complex with phosphoglucomutase-3 (PGM- 3), glyoxalase
(GLO) and urine-pepsinogen-5 (Pg-5) (GOtze, 1981).
The genes are divided into three regions (see Figure 1.1.1) and are arranged from the
centromeric to the telomeric end (Porto et. al., 2005) as Class II, Class III and Class I
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genes respectively (Rees, 1997). Class I genes are strictly a-chain genes whereas Class
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The HLA Class II region is divided into three subregions viz. HLA-DR, HLA-DP and HLA-
DQ (Austyn and Wood, 1993). HLA-DP and HLA-DQ both have two a (a 1 and a2) and two
(13i and (32) genes (Austyn and Wood, 1993) whereas HLA-DR has only one monomorphic
a gene (Sayegh et al., 2000) and three 13 13 2 and (33) genes whose product is able to
couple with the a chain resulting in four MHC Class 11 molecules from the three subregions
(Janeway et. al., 2005; Schwartz, I 987).
The position of the genes are ordered as follows, the HLA-D (Class II) region (Giitze, 1981)
closest to the centromere (van Rood et. al., 1981) followed by the diverse Class III region
which spans 120kb (Rees, 1997) thereafter HLA-B, HLA-C, HLA-E, HLA-A, HLA-H,
HLA-G and HLA-F (Margulies, 1999) respectively followed approximately 4 megabases
telomerically from HLA-A by HFE (Gruen and Weissman, 1997; Janeway et. al., 2005;
Porto et. al., 2005 ) which is a hemochromatosis related gene (Porto et. al., 2005).
HLA-A, -B and -C are classical Class I MHC antigens (Schwartz, 1987) and non-classical
Class I antigens include HLA -E, -F, -G (Hviid et. al., 1999; Pozzi et. al., 1998). In addition
to the Class III region, the genes controlling the expression of DR molecules are present
between the HLA-D and HLA-B region (GOtze, 1981).
Proteins that are responsible for antigen processing and presentation of Class I molecules
(LMP2; LMP7 and TAP1; TAP2) as well as Class II molecules (HLA DM) have the genes
that encode them in the Class II region (Bennetts et. al., 1999; Chevrier et. al., 1998; Rees,
1997). TAP genes lie between DQB1 and DPA1 (Alvarado-Guerri et. al., 2005). In close
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proximity to the centromere lies TAPBP which codes for tapasin (Janeway et. al., 2005).
Also present in the Class II region encoding the DO molecule, are the DNa and D013 genes
(Janeway et.al., 2005).
The Class III region, centromeric to the Class I region (Kimball, 1986), known as the Central
MHC (Gruen and Weissman, 1997; Hauptmann and Bahram, 2004; Noble et. al., 2006) is
located between the Class II and Class I regions (Wright et. al., 2001) and contains genes
unrelated to the Class I and Class II regions viz. complement protein genes C4; Factor B (Bf)
and C2 (Barret, 1988; Janeway et. al., 2005), extracellular matrix protein genes (Tenascin
[TNX]) and Immunoglobulin superfamily gene proteins (1C7; G6f; G6b) (Hauptmann and
Bahram, 2004), hormonal synthesis genes (steroid 21-hydroxylase; CYP21), cytokine
encoding genes (Tumor Necrosis Factor a (TNF-a) and lymphotoxins; LTA (TNF-(3) and
LTB) (Gruen and Weissman, 1997; Janeway et. al., 2005 and Makhatadze, 1998), cellular
stress genes (MICA; MICB) (Janeway et. al., 2005) and Heat Shock Proteins (HSPAIA;
HSPA1B and HSPA 1 L) (Hauptmann and Bahram, 2004). Other cellular stress genes
(MICC; MICD and MICE) are located in the MHC Class I region (Janeway et. al., 2005).
Other genes involved in inflammatory responses are B144, AIF-1, I is B-like and SKI2W
(Gruen and Weissman, 1997). In 1997, Gruen and Weissman suggested that genes which are
involved in inflammation, stress and infection be categorized into a distinct region called the
Class IV region.
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MHC-X lies between HLA-C and HLA-E (Edwards and Hedrick, 1998 and Trowsdale,
2005), occupies 7.6 megabases and is an extension of the Class I and Class II regions and
contains genes that encode histones and tRNA (Trowsdale, 2005).
1.1.4.2 Physical Structure of HLA Class I and Class II Molecules
Chapter 1.1.4.1 focused on the genes which encoded the MHC in humans. I will now
concentrate on the products of the Class I and Class II region of the HLA complex. Class I
and Class II molecules are cell surface receptors (Maenaka and Jones, 1999) which are
structured differently to facilitate different functions in antigen presentation, peptide binding
and T-cell activation (Janeway et. al., 2005).
Both Class I and Class II molecules are heterodimeric (Maenaka and Jones, 1999)
glycoproteins (Austyn and Wood, 2003) which both span the cell membrane (Brodsky, 2001
and Turka, 1997) are composed of four domains which are paired (Janeway et. al., 2005) into
proximal constant and distal variable regions (Wolfe, 1997) and possess a single peptide
binding groove which is able to accommodate a variety of peptides (Abbas and Lichtman,
2003).
1.1.4.2.1 Structure of Class I Molecules
The Class I molecules are made up of two chains, a heavy a chain (Bettinotti et. al., 2003)




a molecular weight of 12 kDa (Sayegh et.al., 2000). The a chain is encoded by Exons 2, 3
and 4 of the MHC and can be distinguished into 5 structural domains, a l - a5 (Austyn and
Wood, 1993; Barret, 1988).
PBR PBR 
Extraccllular




Figure 1.1.2 Diagrammatic representation of MHC Class I (a.) and Class II (b.) molecules. PBR= Peptide
Binding Region. Adapted from Austyn and Wood, 1993; Brodsky, 2001; Sayegh et. al., 2000.
Three of these domains al, a2 and a3 present as folded (Brodsky, 20001) extracellular
domains (Hughes and Yeager, 1998) and form a noncovalent association (Kimball, 1986;
Trinh et. al., 2002) with a soluble (Maenaka and Jones, 1999) polypeptide 132-microglobulin
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((32-m) (Brodsky, 2001) which is encoded by a gene present on chromosome 15 (Janeway et.
al., 2005) (Figure 1.1.2a).
The a chain of the Class I molecule is comprised of three regions (Schwartz, 1987). The first
region is a hydrophobic extracellular region (Schwartz, 1987) which is comprised of al, a 2
and a3 domains (Brodsky, 2001) each comprised of approximately 90 amino acids (Rees,
1997; Schwartz, 1987). The second and third regions are comprised of the a4 and a 5 domains
(Austyn and Wood). These regions are the hydrophobic transmembrane region made up of
about 25 amino acids (Schwartz, 1987) which spans the lipid bilayer (Ausytn and Wood,
1993) and an intracellular, hydrophilic (Schwartz, 1987) cytoplasmic tail made up of about
30 to 40 amino acids (Austyn and Wood, 1993) attached to the a3 domain. The a 3 domain is
the only Class I molecule chain that spans the membrane (Janeway et. al., 2005) thus
anchoring the molecule to the membrane by a carboxy-terminus (Brodsky, 2001).
As documented in Chapter 1.4.2, MHC Class I and Class II molecules are made up of four
domains which are paired. In Class I molecules the relatively conserved (Rees, 1997) a3 and
(3 2 -m domains are paired, placed closest to the cell membrane (membrane proximal domain)
(Austyn and Wood, 1993) and have a structure similar to that of an immunoglobulin domain
(Janeway et. al., 2005; Nikolich-ugich et. al., 2004). The highly polymorphic (Rees, 1997),
variable (Sayegh et. al., 2000; Williams, 2001) a, and a2 domains are paired, placed distal to
the membrane surface (Nikolich-k' ugich et. al., 2004) and folded in a particular way to form
a cleft on the molecule surface (Janeway et. al., 2005). This cleft is the site of peptide
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binding (Williams, 2001) and is designated the peptide binding cleft/groove/region, the ends
of which are closed up by specific hydrophobic residues (Maffei and Harris, 1998).
1.1.4.2.2 Structure of Class II Molecules
Class II molecules are heterodimers (Rees, 1997) comprised of two glycosylated (Austyn and
Wood, 1993) polypeptide (Giitze, 1981) chains (Janeway et. al., 2005; Varney et. al., 1999)
viz. a heavy a chain made up of 229 amino acids (Schwartz, 1987) with a molecular weight
of 34kDa (Sayegh et. al., 2000) and a light 13 chain made up of 237 amino acids (Schwartz,
1987) with a molecular weight of 28kDa (Sayegh et. al., 2000). Both chains of Class II
molecules are encoded within the MHC (Janeway et. al., 2005; Laurent and Welsh, 1984) by
different genes (Varney et. al., 1999) and are linked noncovalently (McCluskey and Peh,
1999).
Class II molecules are made up of three regions viz. an extracellular hydrophilic portion
(Schwartz, 1987) where both the a and p chains fold to form two pairs of extracellular
domains (Brodsky, 2001) each made up of about 100 amino acids (Austyn and Wood, 1993),
a hydrophobic (Schwartz, 1987) transmembrane region made up of about 20-25 residues
(Austyn and Wood) and an intracellular hydrophilic (Schwartz, 1987) cytoplasmic tail of
about 3-15 residues in the a chain and 8-20 residues in the 13 chain (Austyn and Wood, 1993)
(Figure 1.1.2b).
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The a chain domains are designated ai and a2 and the p chain domains are designated PI and
13 2 (Brodsky, 2001). Unlike the Class I molecule, there is no association with a 13 2-m domain
(GOtze, 1981); instead al pairs with 131 and a2 pairs with (Austyn and Wood, 1993).
Membrane proximal, Immunoglobulin-like (Schwartz, 1987) domains are a2 and 132 (Austyn
and Wood, 1993). Both these chains span the membrane (Janeway, et. al., 2005) and are
anchored to the membrane by their carboxy termini (Brodsky, 2001).
Membrane distal domains are the a l and 13 1 variable (Williams, 2001) domains. These
domains fold in a specific way to form a peptide binding groove (Schafer et. al., 1995) which
appears open-ended (Maffei and Harris, 1998) and wider in the Class II molecule due to the
type of peptide it binds (Janeway et. al., 2005). Both 13 chain domains as well as the
membrane proximal a domain encompass intrachain disulfide bridges (Sullivan and Amos,
1986).
1.1.5 Crystal Structure of HLA Class I and Class II Molecules
In order to determine HLA structures by x-ray crystallography at a resolution of 3.5A
(Bjorkman et. al., 1987) and 3.3A (Brown et. al., 1993) for Class I and Class II molecules
respectively, the extracellular domains of the molecule had to first be cleaved with papain
from the cell surface before purification (Margulies, 1999). These experiments made it
possible to determine the way the chains fold into a 3-Dimensional structure (Sayegh et. al.,
2000).
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1.1.5.1 Structure of Class I Molecules
Bjorkman et. al. (1987) resolved an HLA Class I molecule (HLA-A2) by X-ray
crystallography. Later a refined structure was determined by Saper et. al. (1991) at a
resolution of 2.6A. Briefly, the peptide binding groove occurs at the surface of the Class I
molecule (Sayegh et. al., 2000) at the NH2 domains, al and a2 (Margulies, 1999) which have
a similar tertiary structure (Austyn and Wood, 1993). External view of the cell indicates the
a3 and 132-m domain pair asymmetrically (Margulies, 1999) proximal to the membrane
surface (comparable to the constant domain of an immunoglobulin molecule) and the al and
a2 domain pair distal to the membrane surface (Austyn and Wood, 1993) with the peptide
binding site facing the exterior (Sayegh et. al., 2000).
The a3 and 13 2 -m domains are made up of two anti-parallel 13-pleated sheets linked by a
disulfide bond, one containing four 13-strands and the other three 13-strands (Bjorkman et. al.,
1987) (See Figure 1.1.3a). The al and a2 domains fold almost symmetrically (Sayegh et. al.,
2000) to form the peptide binding groove. The boundaries of this groove are formed by two
segmented a-helices (Janeway et. al., 2005) and is supported by the floor of the groove
(Margulies, 1999) which is composed of eight anti-parallel 13-strands (Janeway et. al., 2005;
Margulies, 1999; Zacharias and Springer, 2004).
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1.1.5.2 Crystal Structure of Class II Molecules
X-ray crystallography indicates that the Class II molecules are folded almost identically to
the Class I molecules (Brown, 1993) (See Figure 1.1.3b). The difference lies in the heavy
and light chains of the Class II molecule which are joined symmetrically (Nikolich-2ugich et.
al., 2004) as opposed to an asymmetrical association between the Class I molecule domains
(Margulies, 1999) and the space between the ends of the peptide binding groove being more
ajar in the Class II molecules than the Class I molecules (Janeway et. al., 2005; Sayegh et.
al., 2000). The antigenic peptides are bound to the MHC Class II molecules via hydrogen
bonds (Stern et. al., 1994).
1.1.6 Tissue Distribution and Expression of HLA Class I and Class II Molecules
Class I molecules are found on almost every (Schwartz, 1987) somatic (Austyn and Wood,
1993) nucleated (Barrett, 1988) cell as well as platelets (Sayegh et. al., 2000; Williams,
2001). The degree of expression of Class I antigens is determined by the type of cell it
appears on (Austyn and Wood, 1993; Janeway et. al., 2005). For example, muscle cells;
neurons (Austyn and Wood, 1993); kidney cells and even red blood cells display lower or no
levels of expression than cells found in the immune system (Janeway et. al., 2005). The level
of expression however can be elevated by an immune response (Austyn and Wood) usually
during inflammation and induced by cytokines Interferon-y (INF-y) and tumor necrosis factor
(TNF) (Turka, 1997).
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Class II antigens are found predominantly on antigen-presenting cells; B cells and their
precursors (Laurent and Welsh, 1984) immunocompetent cells such as
macrophages/monocytes (Schwartz, 1987) and dendritic cells (Germain, 1994) as well as
endothelial (not generally expressed) (Sayegh et. al., 2000) and epithelial cells (Laurent and
Welsh, 1984), resting (Schwartz, 1987) and activated T cells (Turka, 1997). Cells expressing
Class II molecules are involved in extracellular uptake of antigens as well as triggering
immune responses (Austyn and Wood, 1993).
Expression of Class II molecules are increased in B cells, other antigen presenting cells and
epithelial cells of the thymus but are found to be MHC II-negative in cells of the kidney,
neutrophils and the brain although microglia of the brain are found to be MHC II positive
(Janeway et. al., 2005). The level of expression of Class II molecules are also increased by
inflammatory responses by antigen (Turka, 1997) or cytokines such as INF-y (Austyn and
Wood, 1993). Cells that do not generally express Class II molecules, such as endothelium;
renal proximal tubules and keratinocytes (Turka, 1997) can be stimulated to do so during
inflammation (Sayegh, et. al., 2000; Williams, 2001).
Cells that express both Class I and Class II molecules contain three Class I antigens and three
or more Class II heterodimers (Buckley, 2003). Both MHC Class I and Class II molecules
exist in the serum of healthy individuals and during disease are elevated (Zavazava and
Eggert, 1997).
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1.1.7 Function of The HLA Class I and Class II Molecules
The primary function of HLA Class I and Class II molecules is to bind to peptide derived
fragments and present them extracellularly (Janeway et. al., 2005) via the peptide binding
groove (McCluskey and Peh, 1999) to the receptors of T cells (Battaglia and Gorski, 2002)
enabling them to restrict and regulate specific antigenic responses (Caruso et. al., 2001).
Both Class I and Class II molecules are structured differently to present antigens via different
pathways (Brodsky, 2001). Although antigen presentation occurs via different pathways,
they share a similar antigen binding specificity (Stern et. al., 1994). HLA molecules also
enable the immune system to discriminate between self and non-self proteins (Hutter and
Dohr, 1998).
As mentioned above Class I molecules are present on almost every cell. This makes it
possible for any altered cell to be destroyed by Tc cells whereas the restricted distribution of
MHC Class II molecules assures the exclusive response of TH cells to antigens present on
antigen presenting cells (Kimball, 1986).
1.1.7.1 Function of The Class I Molecule
The main antigens recognized by the host's immune system during tissue graft rejection are
the Class I antigens (Schwartz, 1987) which by and large present peptides derived
exogenously (Maffei and Harris, 1998) in the cytosol (Janeway et. al., 2005). These peptides
are generally are self (Bontrop and Watkins, 2005; Caruso et. al., 2001) or derived from
viruses or other intracellular pathogens that exploit the host's protein producing mechanisms
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(Turka, 1997). These pathogens are degraded by catalytic proteases (Jeffery and Bangham,
2000) into small peptides (Abbas and Lichtman, 2003; McCluskey and Peh, 1999),
transported for assembly to the endoplasmic reticulum (ER) (Germain, 1994; Jeffery and
Bangham, 2000) by means of an active transport process (Tussey et al., 1995) by TAP
(Faulkner et al., 1998; Petrovsky and Brusic, 2004) (Transporter associated with Antigen
Processing) molecules (Turka, 1997) and are presented to CD8 + cytotoxic T lymphocytes
(Hughes and Yeager, 1998; Li and Bouvier, 2005) bound to the peptide binding groove. The
cytoplasmic and transmembrane domains however do not play a role in T cell activation (Gur
et. al., 1999).
Non-classical Class I molecules, HLA-E (Borrego et. al., 1998; Braud et. al., 1998; Brooks
et. al., 1999; Lee et. al., 1998) and HLA-G (Rajagopalan and Long, 1999), present peptides
to Natural Killer (NK) cell receptors (McCluskey and Peh, 1999).
1.1.7.1.1 Antigen Processing and Presentation by The Cytosolic Pathway of Class I
Molecules
Class I presentation of antigenic peptides to MHC CD8+ restricted T cells occurs as follows.
Proteins present in the cytosol are constantly degraded (Janeway et. al., 2005) by a barrel
shaped (McCluskey and Peh, 1999), 20S (Maffei et. al., 1997) 700kDa (Maffei and Harris,
1997) multi-catalytic protease complex known as the proteasome (Janeway et. al., 2005)
(Figure 1.1.4a) into peptides with a length of approximately 8 to 10 amino acids (Janeway et.
al., 2005; Li and Bouvier, 2005; McCluskey and Peh, 1999).
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Once degraded, these peptides are transported from the cytosol to the rough Endoplasmic
Reticulum (RER) (Figure 1.1.4b) by TAP-1 and TAP-2 molecules (Turka, 1997) which form
a channel in the membrane of the RER (Maffei and Harris, 1998) that pumps cytosolic
peptides into the lumen of the RER against an ATP gradient (Brodsky, 2001).
Assembly of MHC Class I molecules occurs in the lumen of the RER and are only released
once the molecule binds to peptide. In the lumen of the RER, the partly folded Class I a
chains bind to a chaperone protein calnexin prior to assembly with P2-m (Janeway et. al.,
2005) (Figure 1.1.4c). Once association of the a chain and P2-m occurs, calnexin dissociates
from the partly folded Class I molecule which thereafter binds to the MHC Class I loading
complex (Janeway et. al., 2005).
The first protein of the MHC Class I loading complex is calreticulin (Janeway et. al., 2005)
which together with calnexin facilitates initial folding and association of the Class I molecule
(Brodsky, 2001). Tapasin (TAPBP) is the next MHC Class I loading complex protein that
binds to the partly folded MHC Class I molecule forming a bridge between TAP and the
Class I molecule and calreticulin (McCluskey and Peh, 1999) (Figure 1.1.4d).
Once antigenic peptides enter the lumen of the RER by the channel formed by the TAP
molecules, the Class I molecule dissociates from its chaperone molecules (Turka, 1997) and
the TAP molecule transports the appropriate peptide to the peptide binding groove of the
















MHC Class I/ Peptide
Complex
Figure 1.1.4 MHC Class I presentation by the Cytosolic Pathway. Explained in detail in text. Adapted from Brodsky,
2001; Janeway et. al., 2005; Parham and Ohta, 1996; Sayegh et. al., 2000.
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The MHC Class I molecule/peptide complex is thereafter budded off into vesicles and
transported to the cell surface (Thorsby, 1997) where they fuse with the cell membrane thus
presenting the MHC Class I/peptide complex (Brodsky, 2001) (Figure 1.1.40 to cytotoxic
(Sayegh et. al., 2000 Mitchison et. al., 1996) CD8 + T cells which bear MHC restricted Class I
T cell receptors (Lederman and Suciu-Foca, 1999).
Another chaperon protein involved in Class I presentation is Erp57 which is postulated to
play a role in the destruction and reconstruction of the disulphide bond in tapasin (Dick et.
al., 2002) present in the MHC Class I a2 domain during peptide loading (Janeway et. al.,
2005).
1.1.7.2 Function of The Class II Molecules
Class II molecules function to maintain self tolerance as well as to induce and maintain
immune responses against foreign invading pathogens (Friese et. al., 2005). The Class II
molecules are produced in the RER (Thorsby, 1997) and present extracellular peptides
(Wright et. al., 2001) which are derived endogenously (Maffei and Harris, 1998) in
membranous endosomal vesicles (Brodsky, 2001) from proteins which are seized by and
taken in to the cell via fluid-phase pinocytosis, phagocytosis or receptor-mediated
endocytosis (Brodsky, 2001; Rodriguez-Pinto, 2005).
The peptides presented by MHC Class II molecules are up to 16 amino acids in length
(Nikolich-ugich et. al., 2004) and could possibly be derived from parasites (Turka, 1997)
37
processed bacteria such as mycobacteria (the causative agent of tuberculosis) (Janeway et.
al., 2005) or intact viruses particles (Turka, 1997) and presented to CD4 + T helper (TH) cells
(Bontrop and Watkins, 2005) which bear MHC class II restricted T cell Receptors (Lederman
and Suciu-Foca, 1999).
Naïve TH cells are differentiated into two classes of CD4+ T helper cells (Middleton et. al.,
2002) viz. TH1 and TH2 cells (Janeway et. al., 2005) by NK cells (Middleton et. al., 2002).
Once the MHC Class II molecule binds to the CD4 + T cell it provokes the T cells to either
release proinflammatory cytokines (Turka, 1997) which will either destroy the pathogen if
the antigen presenting cell its bound to is a macrophage (Wright et. al., 2001) in the case of
disease-inducing (Mitchison et. al., 1996) TH 1 cells (Janeway et. al., 2005) or control the
production of antibody (Bontrop and Watkins, 2005) by antigen presenting B cells in the case
of protective (Mitchison et. al., 1996) TH2 cells (Janeway et. al., 2005).
1.1.7.2.1. Antigen Processing and Presentation by The Endocytic Pathway of Class II
Molecules
Antigen processing by the endocytic pathway occurs as follows. Antigenic proteins are
protected from the cytosolic proteasomes by their initially neutral membrane bound vesicles
(Janeway et. al., 2005) (Figure 1.1.5a). As the vesicle moves into the cell the pH decreases
to an acidic state resulting in protein degradation (Janeway et. al., 2005; Turka, 1997) into














Figure 1.1.5 Diagrammatic representation of the MHC Class II pathway. Explained in detail in text. Adapted
from Brodsky, 2001; Janeway et. a1.,2005; Macnaka and Jones, 1999.
39
The MHC Class II a and 13 chains assemble to form the MHC Class II molecule in the RER
(Brodsky, 2001; Schafer et. al., 1995) (Figure 1.1.5c). In order to prevent the MHC Class II
molecule from binding to other peptides in the ER (Turka, 1997) prior to fusion with an
endocytic peptide containing vesicle, the peptide binding groove becomes occupied by a non
polymorphic (Brodsky, 2001) invariant chain (Ii) (Maenaka and Jones, 1999) (Figure 1.1.5d).
The MHCIIIIi complex is delivered to vesicles by the invariant chain (Janeway et. al., 2005).
These MHCII/Ii complex containing vesicles bud out of the ER via the golgi apparatus into
the endocytic pathway (Brodsky, 2001) (Figure 1.1.5e). The invariant chain becomes
cleaved by acid proteases (Janeway et. al., 2005) such as cathepsins (B, D and S) as they
develop into prelysosomes (Brodsky, 2001) into a shorter peptide called CLIP (Class II-
associated invariant chain peptide) (Janeway et. al., 2005) (Figure 1.1.50.
Vesicles containing newly formed MHC molecules move towards the surface of the cell
where they encounter vesicles containing antigenic peptides. Both the peptide containing
endosomes and the MHCII/Ii-containing lysosomes fuse but the MHC Class II molecule still
holds the CLIP molecule in its peptide binding groove and is thus unable to bind peptide
(Janeway et. al., 2005) (Figure 1.1.5g).
CLIP is dissociated from the MHC Class II molecule by the nonclassical HLA-DM molecule
(Maenaka and Jones, 1999) which stabilizes the empty MHC Class II molecule (Watts, 2001)
by preventing premature peptide binding (Figure 1.1.5h). This dissociation is negatively
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(Janeway et. al., 2005) controlled (Rodriguez-Pinto, 2005) by HLA-DO which inhibits the
release of CLIP from MHC Class II molecules by HLA-DM (Janeway et. al., 2005).
Once CLIP is released by HLA-DM from the peptide binding groove of the MHC Class II
molecule, antigenic peptides from the now fused endosome/lysosome are able to bind to the
empty groove (Janeway et. al., 2005).
The entire vesicle thereafter moves to the cell surface where it fuses with the cell membrane
resulting in the MHC Class II/peptide complex being presented at the cell surface of the
antigen presenting cell (Schafer, 1995) to the T Cell Receptors of CD4 + cells which binds to
the 132 domain of the MHC Class II molecule (Brodsky, 2001) (Figure 1.1.5i). This
interaction results in the activation and expansion of the CD4 + cells which thereafter mount
immune responses that act to destroy the pathogen whose antigens are presented by the MHC
Class II molecules (Friese et. al., 2005).
1.1.8 Linkage Equilibrium and Disequilibrium





2pq + q2) whereby two conclusions can be derived viz. 1. After first generation mating, the
progeny will present with a genotype frequency of p 2 AA: 2 pq AB: q2BB for the two alleles
(A and B) and, 2. The frequency of this distribution in migration-, mutation- and selection-
free environments will remain constant during subsequent generations thus maintaining the
population in equilibrium (GOtze, 1981).
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A deviation from this equilibrium results in disequilibrium. Linkage disequilibrium is a
nonrandom association (Payne, 1977) of two different antigens (Braun, 1979) located at
separate loci on the same chromosome (Mackay and Powell, 2006) in a population which are
present in frequencies which greatly exceed the anticipated and calculated as the difference
(A) between the expected and observed frequencies (Schwartz, 1987).  Linkage
disequilibrium is caused by genetic drift, mutation, population bottlenecks, founder effects,
migration, selection and admixture (Mackay and Powell, 2006; Weeks and Lathrop, 1995).
Studying this phenomenon can only be possible in outbred populations which comprise large
numbers of diverse haplotypes (van Rood et. al., 1981). For example, in population x, the
frequencies of HLA-A2 and HLA-DR7 occur with frequencies of 0.17 and 0.09 respectively.
The expected frequency of the HLA-A2-DR7 haplotype would thus be 0.17 x 0.09, or 0.0153
but the actual frequency of the haplotype is 0.0812. Hence the linkage disequilibrium (A) is
0.0812 — 0.0153 = 0.0659.
In general loci said to be in linkage disequilibrium are physically closely related. Palmer and
Cardon (2005) and Wenda et. al. (2006) showed that lack of linkage disequilibria is due to
the great physical distance between 6 STR loci examined.
Linkage disequilibrium has been demonstrated to be present between the classical Class II
HLA-DR3 and the non-classical Class lb HLA-G010102 (Vauvert et. al., 2005).
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Decay of linkage disequilibrium occurs with time in large populations (Park et. al., 2007) due
to meiotic (Palmer and Cardon, 2005) recombinations (Mackay and Powell, 2006; Palmer
and Cardon, 2005; Weeks and Lathrop, 1995) at a rate determined by the distance between
loci (Mackay and Powell, 2006; Weeks and Lathrop, 1995) over successive generations
(Mackay and Powell, 2006; Palmer and Cardon, 2005) in the absence of disturbing factors
such as migration (Park et. al., 2007). Rapid decay of linkage disequilibrium occurs due to
selection, drift or admixture and slower decay is due to closely linked loci (Weeks and
Lathrop, 1995).
1.1.9 MHC Polymorphism
MHC polymorphism refers to the allelic variation derived from the MHC Class I and Class II
genes which is present in a population at any given time in amounts that are greater than
expected (Margulies, 1999). This variation may be due to gene conversion, recombination
and exon shuffling events (Adams et. al., 2004) and is considered to be aggravated and
sustained by the ancient mëlée between our immune system and infectious pathogens (Beck
et. al., 1999)
Class I genes in humans display two alleles for each of the three classical HLA-A, HLA-B
and HLA-C genes (Bettinotti et. a/., 2003) and Class II genes display three to four sets of
genes resulting in expression of six distinct Class I molecules and eight distinct Class II
molecules (Janeway et. al., 2005).
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Both Class I and Class II molecules are highly polymorphic and their polymorphism lies in
their membrane distal NH 2 termini (Maffei and Harris, 1998; Sayegh et. al., 2000) which fold
to form the peptide binding groove thus signifying the importance of polymorphism which is
required to allow the molecule and consequently the entire organism and species to react to a
change in the antigenic environment (Margulies, 1999). Although Class II molecules are
highly polymorphic, allelic variation of their a chains is limited (Turka, 1997). Their
polymorphism thus lies in the 13 chain (Laurent and Welsh, 1984).
By and large polymorphisms arise from the variability of the amino acid side chains of the
peptide anchor residues (Bontrop, 2006; Janeway et. al., 2005) which bind to complementary
polymorphic (Zhang et. al., 1998) pockets lining the peptide binding groove (Bontrop and
Watkins, 2005; Janeway et. al., 2005; Marguiles, 1999). These pockets are formed by
polymorphic residues (Li and Bouvier, 2005). There are 48 Class I MHC pockets which are
classified into pocket families by similarities in their side-chain binding specificity and
physical attributes (Zhang et. al., 1998).
Polymorphisms in the Class I molecules line the floor of the peptide binding groove (Kostyu
et. al., 1997; Sullivan et. al., 2006), are clustered in Hypervariable (H,) regions (Male et. al.,
1996) present in the al and a2 domains (which are encoded by exon 2 and exon 3) (Tiercy,
2002) as well as the loops outside the peptide binding groove (Kostyu et. a/., 1997) and
influence the binding specificity of the pockets by selecting the amino acids which bind to it.
Even a single amino acid substitution at a given position may change the binding specificity
altogether (Zhang et. al., 1998).
44
Each MHC class I variant has a specific anchor residue (Janeway et. al., 2005). This specific
anchor residue is called the sequence motif (Janeway et. al., 2005). Variability is shown to
be greater in the a helix of the ai domain as compared to the a2 domain but greater in the a2
13-strand region as compared to the (3-strand region of a l (Parham et. al., 1988).
Polymorphic residues in Class II molecules rest in clusters that make up the Hv regions where
they line the sides and floor of the peptide binding groove (Maffei and Harris, 1998).
Polymorphism of Class II molecules are mostly exhibited on HLA-DRB, HLA-DQB, HLA-
DPB and HLA-DQA as HLA-DPA is for the most part non-polymorphic and HLA-DRB is
monomorphic/invariant (Male et. al., 1996).
When polymorphism occurs outside the peptide binding groove, it does not affect antigen
binding specificity as in the case of HLA-B*5133 (Lebedeva et. al., 2003).
MHC polymorphism is beneficial due to the fact that allelic variation between individuals
provides resistance to infectious agents (Leffell, 2002) and prevents a particular pathogen
from causing extinction of an entire population (Bontrop, 2006; Bontrop and Watkins, 2005).
1.1.10 HLA and Disease Associations
HLA has been demonstrated to be associated with various diseases in different populations
(Bassett et. al., 1979; Rossman et. al., 2002). HLA genes are also protective (by prevention
of progression of HIV disease) (Migueles et. al., 2000). These diseases encompass non-
45
infectious (Van Rood et. al., 1981) autoimmune, infectious and the sequelae of certain
infectious diseases which may be autoimmune (GOtze and Burger, 1986). In order to
determine disease susceptibility or resistance, population or family studies or both need to be
conducted (Svejgaard, 1986).
Genes found to protect against a disease are on occasion found at lower frequencies in a
diseased population as compared to disease susceptibility genes (Mitchison et. al., 1996).
The presence of an antigen is not indicative of disease susceptibility (Gotze and Burger,
1986). Therefore in order to determine associations, the gene frequencies of the diseased
population must be compared with a population of healthy controls (Mitchison et. al., 1996).
In population studies, the relative risk is used to calculate the strength of the association
between HLA and the population in question (Van Rood et. al., 1981) thereafter statistical
significance can be determined by the Fisher's exact or chi-square tests (Svejgaard and
Ryder, 1977).
The relative risk is basically the cross-product ratio of patients and controls in a population
with and without the antigen of interest (Svejgaard, 1986) and it indicates how more
regularly the disease occurs among individuals bearing the antigen compared to those that are
not (Van Rood et. al., 1981). When the frequency of an antigen is greater in the diseased
population as compared to the healthy controls, a relative risk greater than one is observed
indicating an increased risk and vice versa but a relative risk equal to one indicates no
difference between the control and diseased populations (Svejgaard, 1986).
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Family studies are carried out in addition to population studies to better understand the
genetics of the disease (Svejgaard, 1986) and could possibly indicate a linkage between
disease susceptibility and HLA alleles between diseased family members that share
haplotypes present at a greater frequency than would be expected by normal Mendelian
genetics (Van Rood et. al., 1981).
The difference between population and family studies is that population studies are employed
to determine statistically significant associations between a HLA marker gene and a disease
(Schwartz, 1987) whereas family studies are used to establish a linkage between the marker
gene and a major disease-controlling gene (Svejgaard and Ryder, 1977). The terms
associations and linkage cannot be used interchangeably because association does not
consequentially signify linkage and vice versa (Schwartz, 1987). Association is possible
without linkage between two loci and linkage is possible without an association (Svejgaard
and Ryder, 1977).
Patients with steroid-responsive nephrotic syndrome were shown to have an increased
association with HLA-DR7 (relative risk 4.5, p < 0.001) and decreased association with
HLA-DR2 (relative risk 0.23, p < 0.005) when compared to a control group (Nunez-Roldan
et. al., 1982). From the text we can therefore conclude due to the relative risk of HLA-DR7
being greater than 1 and the relative risk of HLA-DR2 being less than 1 that HLA-DR7 is a
possible disease susceptibility gene and HLA-DR2 is a possible protective allele.
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Another potent association has been found between idiopathic membranous nephropathy
patients and the HLA-DRw3 allele (relative risk 12.0, p value = 0.00000034) when compared
to a control group (Klouda et. al., 1979). HLA-DRw3 was found in 75% of the patients and
20% of the controls suggesting together with a relative risk greater than 1, that it is a possible
disease susceptibility gene.
An excellent example illustrating the importance of HLA associated studies was carried out
by Kiepiela et al. (2004) demonstrating that HIV infected antenatal mothers carrying
protective HLA-B alleles (HLA-B*57 and HLA-B*5801) pass on HIV to their children less
frequently than infected antenatal mothers carrying the deleterious (HLA-B*5802 and HLA-
B*18) alleles. These findings indicate that as the pandemic advances, the frequencies of
HLA-B*5802 and HLA-B*18 will decrease and that of HLA-B*57 and HLA-B*5801 will
increase rapidly.
1.2 The Kidney
The kidneys function to excrete nitrogenous (Wallace et. al., 1996) waste products of
metabolism, regulate the water and electrolyte balance, maintain the acid-base balance (Snell,
2004), regulate the body fluid osmolality, electrolyte concentration and arterial pressure and
is involved in gluconeogenesis (Guyton and Hall, 2006) and play a role in erythropoiesis and
calcium homeostasis. Generation of de novo nephrons is not possible hence nephrons that
are destroyed due to renal injury, renal disease or natural ageing cannot be replaced (Guyton
and Hall, 2006).
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1.2.1 Functional Anatomy of The Kidney
From the outside both human kidneys appear to be smooth bean shaped organs (Harrison,
1981) which are located on the upper end of the posterior abdominal wall (Last, 1990) and
positioned obliquely with the right kidney lying lower due to the magnitude of the right lobe
of the liver (Snell, 2004). Normal dimensions of a kidney are usually 12 x 6 x 3 cm with a
weight of 130 g (Last, 1990) and although both kidneys have roughly the same size and
shape, the left kidney appears to be more elongated and slender (Drake et. al., 2005).
The kidney encompasses upper (contiguous to the supra renal glands) and lower poles at the
extremities (Green and Silver, 1981), it has smooth anterior and posterior surfaces in the
presence of lobulation (Last, 1990) and is enclosed by a fibrous capsule (Drake et. al., 2005)
and medial which is a deep concavity that advances into a void which is the sinus of the
kidney (Green and Silver, 1981). Entrance into the sinus occurs via the hilum (Green and
Silver, 1981) which is a vertical slit fringed by thick lips of renal matter (Snell, 2004)
extending almost half way up (Green and Silver, 1981) on the medial margin of the kidney
(Drake et. al., 2005) (see Figure 1.2.1).
In the renal sinus, two to three minor calyces come together to form a major calyx (Drake et.
al., 2005) and two to three major calyces make up the renal pelvis (Snell, 2004) which is the
urine collecting (Wallace et. al., 1996) upper end of the ureter displaying a funnel shaped














Passing through the hilum are lymph vessels, sympathetic fibres, the renal vein, two branches
of the renal artery (Snell, 2004), the pelvis of the ureter (Harrison, 1981) and a third branch
Renal pelvis
Figure 1.2.1 Diagrammatic representation of a human kidney. Functional anatomy explained in text. Adapted from
Drake et. al., 2005; Wallace et. al., 1996.
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of the renal artery (Snell, 2004). The renal artery enters the kidney via the hilum whilst the
renal vein and pelvis leave the kidney via the same path (Harrison, 1981).
On the outer surface covering the easily removable fibrous capsule is perirenal (perinephric)
fat surrounded by extraperitoneal (renal) fascia (Drake et. al., 2005) which is condensation of
connective tissue enclosing the kidney and suprarenal glands (Snell, 2004).
The kidney comprises a distinctively striated (Harrison, 1981) dark brown outer renal cortex
and a light brown inner renal medulla (Snell, 2004). The outer renal cortex is an
uninterrupted stretch of pale tissue which encircles the renal medulla entirely (Drake et. al.,
2005) extending into columns between pyramids in the inner renal medulla (Snell, 2004).
Cells that make up the cortex are the cortical labyrinth and the medullary rays (Kriz and
Kaissling, 1985). The medullary rays extend from the base of the pyramid into the cortex
(Snell, 2004).
The inner medulla comprises several conical masses (Harrison, 1981) which employ the form
of a pyramid (Drake et. al., 2005). The base of the pyramid is comprised of alternate dark
and light striations (Harrison, 1981) and faces the renal cortex whilst the apex which is
known as renal papilla or crest (Kriz and Kaissling, 1985) is light coloured, faintly streaked
(Harrison, 1981) encircled by a minor calyx and projects medially towards the renal sinus
(Snell, 2004).
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The cortex comprises the nephrons which are the structural (Kriz and Kaissling, 1985)
filtering components of the kidney whilst the medulla consists mainly of the loop of Henle
(de Wardener, 1985) and the collecting ducts (Wallace et. al., 1996) several of which merge
in the inner medulla forming the ducts of Bellini (Yagoob, 2005) which drain their contents
at the surface of the papilla (de Wardener, 1985) into the calices (Yagoob, 2005).
There are three types of nephrons which are location determined viz. superficial, midcortical
and juxtamedullary nephrons (Kriz and Kaissling, 1985). Each human kidney consists of
approximately 1.3 x 10
6
 nephrons (Ganong, 2005) with each having a width of approximately
25/um and a length of about 50 mm (de Wardener, 1985). The nephron is made up of a renal
tubule and a glomerulus (Ganong, 2005) which is enveloped by epithelial cells (Guyton and
Hall, 2006) and enclosed by a structure called the Bowman's capsule (Wallace et. al., 1996)
(see Figure 1.2.2a).
The tubule of the nephron is divided into a proximal convoluted tubule with a length of
approximately 15 mm and a diameter of 55 (Ganong, 2005), the loop of Henle and a
distal convoluted tubule which eventually leads into a collecting duct (de Wardener, 1985).
Proximal tubules that present towards the surface of the cortex contain shorter loops than
those embedded deep within the cortex (de Wardener, 1985; Kriz and Kaissling, 1985) at a
ratio of 1:4 respectively (de Wardener, 1985). The fluid filtered by the glomerulus is
converted to urine that eventually drains into the pelvis of the kidney (Guyton and Hall,
2006).
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The glomerulus is 200 p.m in diameter (Ganong, 2005) and is made up of four vital cell types
viz. 1. the endothelial cells fenestrated with pores 500-1000 A (Yagoob, 2005) with a
diameter of 70-90 nm (Alpers, 2005); 2. mesangial cells which are contractile and are known
to play roles in glomerular filtration and in the establishment of glomerular disease (Ganong,
2005); 3. epithelial cells of the visceral layer (Kriz and Kaissling, 1985) called podocytes
which sustains the fragile glomerular basement membrane (basal lamina) via a pseudopodia
network (Yagoob, 2005) and interdigitate the capillary wall forming slits that are 50 x 120 A
approximately 25 nm wide (Ganong, 2005) which are smaller than an albumin molecule
(Govan et. al., 1995) and linked by a slit diaphragm (Kriz, 2005) and 4. epithelial cells which
surround the Bowman's capsule (Yagoob, 2005) called parietal epithelial cells (Kwoh et. al.,
2006).
The glomerular tuft contains a mass of approximately five thin walled capillary loops (de
Wardener, 1985; Wallace et. al., 1996) sourced at the afferent vessel and drained by a
smaller efferent vessel (Ganong, 2005). The efferent vessel branches out into peritubular
capillaries (Yagoob, 2005) forming a network that extends over the whole nephron thereafter
merging with peritubular capillaries from other nephrons forming the renal vein (Wallace et.
al., 1996).
In the Bowman's capsule there are two layers of cells that divide the blood from the
glomerular filtrate viz. the capillary endothelium and the specialized epithelium of the
capsule (Ganong, 2005) (see Figure 1.2.2). The endothelium and epithelium are divided by
the basal lamina (Ganong, 2005). Mesangial cells are derived from mesenchymal
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cells (de Wardener, 1985) and are found between the basal lamina and endothelium
(Ganong, 2005) as well as the central stalk of the glomerulus which has a hollow external
surface which forms the lumen of the capillary (de Wardener, 1985).
The glomerular membrane is composed of type IV collagen and negatively charged
proteoglycans and has a thick central layer called the lamina densa which is surrounded
by two layers called the lamina rara interna and the lamina rara externa (Yacioob, 2005).
It is selectively permeable and allows neutral substances with a diameter of up to 4 nm to
traverse the membrane (Ganong, 2005). The lamina densa and the slit diaphragm
covering the pores formed by the epithelial cell foot processes form the vital filtration
barrier (Govan et. al., 1995).
As mentioned above blood enters the glomeruli via the afferent vessels which are
subdivisions of the renal artery (Yacioob, 2005). Both renal arteries receive 25% of
cardiac output (Yacioob, 2005) from the most important artery in the body, the aorta
(Wallace et. al., 1996) hence there is a great hydrostatic pressure of approximately 60
mmHg (Guyton and Hall, 2006) in the capillaries of the glomerulus indicating that high
pressure is essential for optimal functioning of the kidneys (Wallace et. al., 1996).
1.2.2 Overview of Kidney Physiology
Everyday the kidneys function to produce urine by filtering more than 1700 liters of
blood (Alpers, 2005). In addition they excrete the waste products of metabolism, regulate
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salt and water concentration, maintain acid base balance and secrete hormones such as
erythropoietin, renin and prostaglandins (Alpers, 2005).
As mentioned above the nephron is the functional unit of the kidney hence in this chapter
kidney physiology will focus primarily on the physiology of the nephron. The nephron
consists of several regions and each region has a distinct function (Govan et. al., 1995).
The glomerulus functions as the filtration unit of the nephron due to the large surface area
of the capillaries as well as its characteristic composition (Govan et. al., 1995). The
products of filtration are entirely free of blood cells and almost always free of protein due
to the nature of the physiochemical and electrostatic charges of the filtration barrier
(Brady et. al., 2005). The production rate of the filtrate depends on the afferent arteriolar
hydrostatic pressure, the plasma protein osmotic pressure and the pressure within the
renal tubule (Govan et. al., 1995).
The glomerular filtration rate (GFR) depends on blood flow within the glomerulus,
ultrafiltration pressure and the composition of the filtration barrier which are coordinated
by changes in the tone of the afferent and efferent arterioles and the contractility of the
mesangial cells (Brady et. al., 2005).
The tubule functions to eliminate the body of waste products, maintain normal acid-base
balance and to conserve fluid, electrolytes as well as other vital substances via active
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assimilation by the tubular epithelium, passive exchange between the filtrate and
interstitial tissues and secretion by the tubular epithelium (Govan et. al., 1995).
1.2.3 Glomerular Disease
Due to its complex anatomical structure, diseases of the kidney are divided into four
types according to the morphology affected viz. those affecting the glomeruli, the tubules,
the interstitium and the blood vessels (Alpers, 2005).
In the forthcoming chapters, IgAN, FSGS and MGN will be discussed. These are
diseases predominantly affecting the glomeruli of the kidney.
Glomerular disease is the consequence of injury to glomeruli which may be primary or
due to vascular (e.g. hypertension), metabolic (diabetes), hereditary (Fabry disease),
systemic (SLE) diseases (Alpers, 2005) or genetic factors (some forms of steroid resistanr
nephritic syndrome).
The consequence of glomerular disease is typically threefold viz. the impairment of
glomerular function which results in the reduction in urinary output; the appearance of
protein (proteinuria) and; blood (haematuria) in the urine (Brady et. al., 2005; Govan et.
al., 1995).
57
The mechanisms underlying glomerular disease are as follows (Govan et. al., 1995):
1. Swelling of the endothelium results in diminished blood flow which results in a
reduction of urinary output.
2. Inflammation alters the permeability of the glomerular damage resulting in
proteinuria.
3. Focal loss of epithelium and endothelium results in haematuria and proteinuria.
Both MGN and FSGS are causes of NS which is characterized by gross proteinuria (>3-
3.5 g/d), hypoalbuminemia (<3 g/d) (Alpers, 2005), hyperlipidemia, lipiduria, thrombotic
diathesis, generalized oedema and a slow decline in GFR (Brady et. al., 2005) and MGN,
FSGS and IgAN are glomerular diseases which result in chronic glomerulonephritis (GN)
which result in ESRD (Alpers, 2005).
Hypertension is an increasing global problem (Kearny et. al., 2004) defined as elevated
blood pressure and it accelerates the progression to renal disease (Ritz and Fliser, 1993).
Six million South African adults are already affected and a westernized lifestyle has been
postulated to augment the numbers (Steyn et. al., 2001). Renal disease is a secondary
cause of hypertension. Race has been shown to affect the prevalence of hypertension and
diet (fat and salt) has been argued to increase blood pressure. Hypertension has been
shown to be the main cause of ESRD in KZN in the African and Indian populations
(Seedat et. al., 1984).
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In view of the global problem of hypertension it becomes increasingly important to
screen patients (Kearny et. al., 2004). Although monitoring a patient's blood pressure
over time and testing serum creatinine levels are the common methods employed, it
requires the patient to be present on several occasions. This is not feasible in poor
communities where patients are unable to attend public health care centres due to lack of
travel money. Genome screens would involve analysis of the entire genetic profile
(Chow et. al., 2005) and would be futile if only certain genes were involved in disease
progression. Therefore a practical alternative would be to first detect disease
susceptibility markers present in the HLA complex and thereafter screen patients for
these marker alleles.
1.2.4 IgA Nephropathy (IgAN)
IgA Nephropathy is an immune-complex mediated (Wardle, 2004) and the most
widespread type of primary GN globally (Lai and Lai, 2005) resulting in fifteen to forty
percent of patients (Donadio and Grande, 2002) progressing to ESRD (Olson, 2001).
IgAN is also known as Berger's disease as it was initially discovered by Berger in 1968.
The molecules that are produced by tonsillar lymphocytes during IgAN are under-o-
glycosylated suggesting that tonsils play a major role in IgAN as they showed to provide
the bulk of the underglycosylated IgAl which are deposited into the glomeruli during the
disease (Horie et. al., 2003). Inflammation in IgAN is a result of the segregation of IgA 1
in the mesangial cells of the renal glomeruli (Van Es, 1997; Wardle, 2004) therefore
studies related to IgAN rarely involve its relation with the upper respiratory tract
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(Wardle, 2004) yet rather they tend to center on reducing the damage of the glomeruli
(Lai, 2002).
IgAN in the absence of a clinical precursor or association is referred to as primary IgAN
whereas IgAN in association with other diseases is referred to as secondary IgAN (Floege
and Feehally, 2000).
1.2.4.1 Aetiology
Aetiology of IgAN is unknown (Donadio and Grande, 2002) but the establishment or
aggravation of disease is typically led by upper respiratory tract infections (Brake and
Somers, 2006).
1.2.4.2 Morphology
Biopsy reveals focal and segmental proliferative glomerular lesions with polymeric IgAl
(pIgA 1) deposited in mesangial cells (Yacioob, 2005), interstitial fibrosis, arterial
arteriolar changes (Nicholls et. al., 1984) and crescents during rapid disease progression
(Goddard et. al., 2006).
1.2.4.3 Clinical Features
By and large patients are asymptomatic at the onset of the disease resulting in patients
being ignorant of the disease until it is surmised to be IgAN during regular screening or
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while examining some other disease (Donadio and Grande, 2002) e.g. hypertension
(Nicholls et. al., 1984). A number of patients may possibly display aggressive disease
(Donadio and Grande, 2002).
Typical clinical features of primary IgAN include episodic macroscopic haematuria
concurrent with an upper respiratory tract infection (Donadio and Grande, 2002)
persisting proteinuria, persistent or intermittent microscopic haematuria, chronic renal
failure (CRF) and hypertension and they occur prominently in patients greater than 25
years of age (Clarkson et. al., 1999; Olson, 2001).
About 50% of patients with IgAN generally present with sudden commencement of gross
haematuria which is occasionally associated with pain in the flank and increased protein
excretion two to three days after an upper respiratory tract or gastrointestinal viral
infection (Couser, 1999).
A minute proportion of patients with IgAN will present with azotemia a portion of which
may require dialysis indicating the most aggressive type of the disease (Donadio and
Grande, 1997) due to late diagnosis (Donadio and Grande, 2002).
Recurrent IgAN following renal transplantation is not a benign disease (Floege et. al.,
1998) and it presents as microscopic haematuria (Clarkson et. al., 1999; Kishi et. al.,
2004) as macroscopic haematuria is uncommon (Clarkson et. al., 1999) or proteinuria
(Kishi et. al., 2004).
61
Clinical features indicating poor prognosis include older patients with hypertension,
heavy proteinuria and impaired renal function at diagnosis (Harper and Savage, 1999).
1.2.4.4 Diagnosis
Primary IgAN has no serological abnormalities (Couser, 1999) hence serological markers
cannot be used in diagnosing disease. Although diagnosing IgAN is said to be strictly
biopsy- and immunohistological examination-dependent (Donadio and Grande, 2002)
analysis of protein patterns in urine with the aid of capillary electrophoresis on-line
attached to a mass spectrophotometer (partly due to its sensitivity) could provide an
alternative to invasive biopsies in diagnosing IgAN (Haubitz et. al., 2005).
In biopsy, mesangial IgA deposits can be observed to be associated with IgAN by
immunofluorescence (Kishi et. al., 2004), focal or diffuse mild mesangial cell and matrix
expansion by light microscopy (Donadio and Grande, 1997) and electron dense
mesangial deposits by electron microscopy (McKay et. al., 2000). The observations by
light microscopy are commonly present in other renal diseases hence it cannot be used as
a definitive tool to diagnose IgAN (Donadio and Grande, 1997).
There are a variety of diseases that present with IgA deposits in mesengial cells therefore
the differential diagnosis of IgAN would be that IgAN occurs in the absence of systemic
diseases such as systemic lupus erythematosus (SLE) (Harper and Savage, 1999).
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1.2.4.5 Pathology
In general the most common deviation from the normal anatomy is the expansion of the
mesangial region including the cells and matrix (Donadio and Grande, 2002; Olson,
2001) but this presentation cannot be used to distinctively diagnose IgAN as this disease
process also occurs in other renal diseases (Donadio and Grande, 2002). Crescents
involving in excess of 70% of the glomeruli are indicative of poor prognosis (Oslon,
2001).
1.2.4.6 Pathogenesis
The pathogenesis of IgAN is not yet known (Goddard et. al., 2006) but it is postulated to
be the consequence of a magnified tonsillar IgAl and bone marrow immune response to
antigens (Yaqoob, 2005). In addition an abnormality in the 0-linked galactosylation of
the hinge region of the Heavy chain of the IgA 1 molecule is alleged to play a role in
IgAN by playing a role in the development of macromolecular IgA resulting in its
glomerular deposition in IgAN (Hiki et. al., 1998).
Proinflammatory cytokines (IL-8) (Lai et. al., 1996; Lim et. al., 2001) and a high
proportion of TH1 and TH2 have been shown to influence the severity of pathogenesis and
clinical features of the disease (Lim et. al., 2001). Also IgAN can be stimulated by a
mycotoxin called deoxynivalenol and further promoted by the absence of the
cyclooxygenase-2 (COX-2) gene (Jia and Pestka, 2005).
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Oxidative stress levels are increased in patients with IgAN resulting in the oxidation of
vital amino acids which in turn may well stimulate protein damage ultimately leading to
loss of enzymatic activity and structural integrity (Tfiri et. al., 1997).
IgAN can be transmitted from a living donor to recipient in a silent form via mesangial
IgA deposits during a kidney transplant however prognosis for the recipient has proved to
be more superior to that of the donor (Koselj et. al., 1997).
1.2.4.7 Treatment
The type and option of treatment are restricted as it is difficult to differentiate patients
with good and bad prognosis due to the frequent benign occurrence of IgAN (Harper and
Savage, 1999). By and large treatment of IgAN is symptomatic (Couser, 1999).
Patients have been shown to be treated effectively with Mycophenolate mofetil (Nowack
et. al., 1997). Paediatric patients diagnosed early with severe IgAN displayed reduced
proteinuria and serum IgA levels as well as a decreased concentration of mesangial IgA
deposits when treated with a combination of prednisolone, azathioprine, heparin-warfarin
and dipyridamole thus inhibiting immunologic renal injury as well as disease progression
(Yoshikawa and Ito, 1999). This is postulated to be valid in the adult population as well
(Yoshikawa and Ito, 1999).
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Tonsillectomy (Akagi et. al., 2003; Komatsu et. al., 2005) and steroid therapy have been
postulated to improve renal function and thus prognosis of patients with IgAN (Komatsu
et. al., 2005). In addition oral and intravenous administration of a long course of steroids
proved to be effective in impeding the loss of renal function (Pozzi et. al., 1999). The
gold standard of treatment for patients progressing to ESRD is renal transplantation
(Donadio and Grande, 2002).
Due to the increased oxidative stress, management of IgAN could be aided by antioxidant
therapy and diet (Thri et. al., 1997).
A non pharmacological alternative to treatment of IgAN is via the use of fish oil
supplementation (Donadio et. al., 1994; Grande and Donadio, 1998) but this remains to
be controversial due to its varying therapeutic properties in different populations thus
requiring further investigations (Dillon, 1997).
1.2.4.8 Disease Association
Tonsillitis and upper respiratory infections such as bronchiolitis are associated with IgAN
(Wardle, 2004) and transitory associations are found with pharyngitis and gastroenteritis
(Olson, 2001). IgAN was reported to follow pulmonary tuberculosis (TB) which is a
respiratory tract infection but disappeared after six months of treatment with first line TB
drugs (De Siati et. al., 1999).
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Other diseases associated with IgAN are rheumatoid arthritis, ankylosing spondylitis,
viral diseases such as hepatitis and HIV, celiac disease, Henoch-SchOnlein purpura (HSP)
(Floege and Feehally, 2000) as well as mastitis (Thomas et. al., 1985).
Another reported case was that of an association between IgAN and mycoplasma
pneumoniae infection (Suzuki et. al., 2005) but no significant association has been found
between IgAN and certain common viral infections such as cytomegalovirus (CMV),
Herpes Simplex Virus (HSV), Varicella-Zorster Virus (VZV), Influenza Type A and
Type B Viruses and Epstein-Barr Virus (EBV) (Hung et. al., 1996).
Superimposed IgAN has been demonstrated associated with Type II diabetic patients by
high IgA concentration in the sera of the patients (Kanauchi et. al., 2000).
1.2.5 Focal Segmental Glomerular Sclerosis (FSGS)
Focal Segmental Glomerular Sclerosis is the sclerosis of certain glomeruli (local') with
scarring in particular parts of the glomenilar network (`segmental') (Rossini and Fogo,
2004; Schnaper, 1997). There arc several types of glomerulosclerosis viz. primary FSGS
whereby the cause is unknown hence it is referred to as being 'idiopathic', secondary
FSGS which is associated with diseases or clinical conditions which are known
(Schnaper, 1997), genetic (Khoshnoodi and Tryggvason, 2001; Rossini and Fogo, 2004)
or familial FSGS (Mathis et. al., 1998; Winn et. al., 1999) which have been shown to be
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linked to chromosomes 19 and 11 respectively and recurrent FSGS in transplant patients
(Rossini and Fogo, 2004).
1.2.5 1 Aetiology
The aetiology of primary FSGS is not really known (Govan et. al., 1995) but it appears to
be immunologically related (Brady et. al., 2005). A recent study demonstrated that FSGS
may be induced via exposure to sirolimus at high concentrations (Letavernier et. al.,
2007).
1.2.5 2 Morphology
Histology reveals segmental glomerular scarring and no acute inflammation (Goddard et.
al., 2006). Primary FSGS discloses extensive podocyte effacement, the absence of
electron dense deposits and the absence of immunoglobulins except IgM (Furness et. al.,
2007).
1.2.5.3 Clinical Features
During initial stages, clinical features are comparable to that of Minimal Change GN
(MCGN) but lesions produced by FSGS are progressive (Govan et. al., 1995). Other
features that distinguish FSGS from MCGN are an increased frequency of haematuria;
reduced GFR and hypertension; proteinuria is more frequently nonselective in FSGS;
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FSGS responds to a prolonged course of high dose corticosteroid therapy; there is
progression to chronic glomerulosclerosis; immunofluorescence microscopy may reveal
indistinguishable IgM and C3 deposition in the sclerosed areas (Alpers, 2005) and
accumulation of extracellular matrix within the glomerular capillaries with destruction of
the capillary lumen (Reidy and Kaskel, 2007).
There are several variants of primary FSGS including collapsing glomerulopathy (Alpers,
2005), FSGS not otherwise specified, perihilar variant, cellular variant, and tip variant
(Rossini and Fogo, 2004). Primary FSGS normally presents as idiopathic nephrotic
syndrome in approximately 66% of the patients and approximately 33% as subnephrotic
proteinuria (Brady et. al., 2005) which often advances to ESRD (Gerbase et. al., 1998).
Typical presentation is often massive proteinuria, haematuria, hypertension and presence
of blood and leukocytes in the urine (Brady et. al., 2005; Yaqoob, 2005).
Recurrent FSGS occurs directly after the clamp has been detached from the renal artery
or shortly afterwards (Lesavre and Grtinfeld, 1996) and presents with significant
proteinuria within 24 hours of the patient receiving the graft (Fine, 2007) but sclerosis
may only become evident several weeks later (Rossini and Fogo, 2004) with clinical
recurrence occurring more than a year later (Fine, 2007).
There are also several variants of secondary FSGS viz. FSGS secondary to immune
complex or proliferative disease, secondary to C 1 q nephropathy, secondary to diabetes,
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secondary to reflux nephropathy, secondary to HIV infection and FSGS associated with
arterionephrosclerosis (Rossini and Fogo, 2004).
1.2.5.4 Diagnosis
Light microscopy reveals basement membrane collapse (Alpers, 2005) increased
mesangial accumulation in certain parts of the glomerulus (Schnaper, 1997) and
amorphous hyaline material (Brady et. al., 2005) building up in the adjacent capillary
loops (Schnaper, 1997). Light microscopy may fail to detect segmental lesions if the
biopsy specimen does not contain sufficient glomeruli since these lesions are only present
in certain glomeruli (Alpers, 2005) or if cortico-medullary tissue is not present for the
diagnosis of early lesions.
Electron microscopy is an important tool in diagnosing FSGS as it detects other possible
causes of glomerular scarring which could be assumed to be FSGS by simple light
microscopy (Falk et. al., 2000). Electron microscopy discloses visceral epithelial cell
damage (Brady et. al., 2005) and shows the eradication of the foot processes of the
podocytes (Rossini and Fogo, 2004).
Immunofluorescent microscopy may reveal the accumulation of coarse, granular IgM
with C3 at low levels (Falk et. al., 2000) and fibrin in the sclerosed areas of the glomeruli
(Wilson et. al., 1987) or mesangium (Alpers, 2005). In addition hyalinosis and
thickening of afferent arterioles may be evident (Alpers, 2005).
69
As the disease progresses more glomeruli become involved resulting in more global
sclerosis within each glomerulus and expansion of the mesangial matrix (Alpers, 2005).
Ultimately the entire glomerulus becomes sclerosed with evident tubular atrophy and
interstitial fibrosis (Alpers, 2005).
1.2.5.5 Pathology
Complete sclerosis of the affected glomeruli occurs commencing at the juxtamedullary
glomeruli and dispersing outwards to the outer cortical glomeruli resulting in atrophy of
associated tubules (Govan et. al., 2005). Podocytes are postulated to be the prime target
in FSGS (Lesavre and Grunfeld, 1996).
1.2.5.6 Pathogenesis
A common pathogenic mechanism is proposed for classic and recurrent FSGS (Caridi et.
al., 2006).
In FSGS patients a significant decrease in the number of podocytes as well as decrease in
expression of integrin ct 1 13 3 by podocytes was noted (Chen et. al., 2006). Patients with
FSGS excrete urine with a high concentration of podocytes (Nakamura et. al., 2000)
leading Chen et. al. (2006) to believe that the decrease in the number of podocytes per
glomerulus is due to detachment of podocytes from the GBM into urine as a result of the
decrease in expression of integrin al 133 by podocytes.
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Podocytes are unable to regenerate hence they cannot be replaced if lost resulting in areas
of the glomerulus to be exposed and eradication of the barrier between the glomerular tuft
and Bowman's capsule resulting in the adhesion of the parietal epithelial cells to the
GBM (Kriz, 2003). This phenomenon is referred to as a tuft adhesion and it is through
this lesion that segmental glomerulosclerosis sterns (Kriz, 2003). The tuft adhesion
provides a parietal epithelial fissure through which direct contact between the injured tuft
and interstitium occurs (Kriz, 2003). Misdirected filtration occurs if the capillaries of the
tuft adhesion are perfused resulting in the glomcrular filtrate being directed into the
interstitium rather than the Bowman's space thus triggering local interstitial proliferation
resulting in the misdirected filtrate to be surrounded by fibroblasts (Kriz, 2003).
The sequence of events that follow misdirected filtration result in the ultimate
deterioration of the whole nephron (Kriz, 2003). These events include the formation of
paraglomerular spaces which are predisposed to expansion via the detachment of the
parietal epithelial from the GBM due to continuous misdirected filtration (Kriz, 2003). In
turn this results in an increase in the parietal fissure and advancing rupture of the sclerotic
tuft into the periglomerular space (Kriz, 2003). The other loops of the tuft may become
involved via the vascular pole eventually leading to total sclerosis of the glomerular tuft
(Kriz, 2003).
Collapsing FSGS and HIV associated nephropathy (HIVAN) share a common pathogenic
pathway whereby injury results in dysregulation of the podocyte phenotype which in turn
arbitrates collapse of the glomerular tuft (Barisoni et. al., 1999). This is important as the
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change in podocyte phenotype and not the loss thereof plays an important role in the
pathogenesis of FSGS (Barisoni et. al., 1999).
Recurrent FSGS is due to a circulating factor in the serum which causes the glomeruli to
become permeable to albumin and which may be the cause of proteinuria (Savin et. al.,
1996; Sharma et. al., 1999).
1.2.5.7 Treatment
When treated with Prednisolone, 46.7% of patients with FSGS showed a decrease of
urinary podocytes as well as urinary protein indicating a good response however
treatment with cyclophosphamide as well as mizoribine proved to be ineffective
(Nakamura et. al., 2000).
Cyclosporine is also recommended as an effective drug against FSGS (Cattran, 2003).
Patients with resistance to cyclosporine have been showed to be treated effectively with a
combination of tacrolimus and steroids (Segarra et. al., 2002) but mono-treatment with
tacrolimus have been shown to be successful for only a short-term needing long term
trials to prove its efficacy over long periods (Duncan et. al., 2004). Day et. al. (2002)
showed mycophenolate mofetil to be effective in treating patients with treatment-
resistant, frequently relapsing NS as a result of FSGS.
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Transplantation is the option of choice in FSGS with ESRD but is limited by the high
recurrence rate which is between 30 to 50% for the first and up to 90% for the subsequent
transplant (Valdiva et. al., 2005).
Recurrent FSGS can be successfully treated by plasmapheresis (PP) (Valdiva et. al.,
2005) however not in all cases as reported by Singh et. al. (2006) where recurrent FSGS
occurred in an elderly patient two days after receiving a cadaveric graft which had to be
removed after three months (due to complications and infection) resulting in a rapid
recovery. Plasma Exchange (PE) was shown to reduce the severity of proteinuria in a
patient with FSGS but did not prevent disease progression resulting in graft loss (Akioka
et. al., 2004). A combination of plasmapheresis and cyclophosphamide is the preferred
therapy for recurrent FSGS (Caridi et. al., 2006).
Early corticosteroid withdrawal can also be employed posttransplant as it does not
increase risk of recurrence but rather allows the patient to maintain the full benefits of the
transplanted kidney (Boardman et. al., 2005) but reduction in immunosuppressive drugs
(tacrolimus or cyclosporine together with prednisolone and azathioprine or
mycophenolate mofetil) resulted in the recurrence of FSGS (Akioka et. al., 2006).
A vaccine is proposed to be effective if the circulating factor causing FSGS is identified
(Altschuler, 2001). Since medication against the circulating factor might require ongoing
administration, the patient may be faced with side-effects and possible toxicities. The
author indicates that since a vaccine will not require ongoing administration it would not
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present with side effects or toxicities. He also suggests that the vaccine may possibly
bind to the circulating factor resulting in its eradication or may alter or block the structure
thus causing proteinuria to come to an end.
1.2.5.8 Disease Association
FSGS has been reported to be associated with aplastic anemia (Park et. al., 2004),
strongly associated with HIV in London amongst those of Afro-Caribbean descent
(Connolly et. al., 1995) but rare in Venezuelan populations (Vargas-Arenas et. al., 2002)
as well as cyanotic congenital heart disease (CCHA) (Hida et. al., 2002).
1.2.6 Membranous Glomerulonephritis (MGN)
Until recently MGN was known to be the most common cause of nephrotic syndrome in
adults and is characterized into various stages with lesions consistent with disease
progression (Gluck et. al., 1973).
1.2.6.1 Aetiology
Most cases are idiopathic and have no underlying condition whereas the rest are
associated with various factors such as drugs (e.g. captopril and penicillamine), malignant
tumors, infections (Govan et. al., 1995) systemic lupus erythematosus (SLE), as well as
other autoimmune disorders and are referred to as secondary MGN (Alpers, 2005).
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1.2.6.2 Morphology of MGN
Light microscopy reveals diffuse thickening of the GBM which is distinct upon staining
with periodic acid-Schiff (PAS) (Brady et. al., 2005) with no indication of inflammation
or cellular proliferation (Brady et. al., 2005; Goddard et. al., 2006; Pollak et. al., 1968).
Electron microscopy shows dense immune deposition of irregular nature between the
basement membrane and the epithelial cells (containing effaced foot processes) which
cover it (Alpers, 2005). Basement membrane material protrude between the deposits and
appear as spikes, best seen by silver staining, which gradually thickens forming a dome
like structure that ultimately encloses the deposits (Alpers, 2005).
Immunofluorescence microscopy displays granular IgG and C3 deposition (Alpers, 2005)
as well as the terminal components of complement (C5b-9) along the capillary wall of the
glomerulus (Brady et. al., 2005). As the disease progresses, the thickened membrane
enroaches into the lumen of the capillaries which could possibly result in the mesangium
being sclerosed and gradually total sclerosis of the glomeruli may occur (Alpers, 2005).
1.2.6.3 Clinical Features
Males have been shown to be more prone to MGN than females (Gluck et. al., 1973).
Majority of MGN patients present with nephrotic syndrome with unselective proteinuria
(Brady et. al., 2005). Almost 50% of patients present with microscopic haematuria and
hypertension in approximately 20% of patients at the onset of disease (Brady et. al.,
2005).
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Patients that present with recurrent MGN often display nephrotic-range proteinuria
(McKay et. al., 2000). Elderly males with hypertension, severe proteinuria,
hyperlipidemia and impaired renal function are indicative of poor prognosis (Brady et.
al., 2005).
1.2.6.4 Pathogenesis
Not much is known about the pathogenesis of Idiopathic MGN but IgG and C3
containing electron deposits suggest an immune process (Brady et. al., 2005).
1.2.6.5 Treatment
Prednisone was shown not to have an effect in reducing proteinuria (Pollak et. al., 1968).
High risk patients indicative of disease progression should be offered cytotoxic therapy
(Muirhead, 1999). Cyclophosphamide and chlorambucil can be used with cyclosporine
and could potentially be the treatment of choice if proved to be efficient by further
studies (Muirhead, 1999).
1.2.6.6 Disease Association
MGN has been documented to be associated with benign kidney tumours (Bian et. al.,
2003; Gluck et. al., 1973) as well as malignant tumors (Altiparmak et. al., 2003; Evans
et. al., 2003; Fang et. al., 2001; $ahiner, 2004) Cronkhite-Canada Syndrome (Takeuchi
76
et. al., 2003) inflammatory demyelinating polyradiculoneuropathy (Emsley and Molloy,
2002; Mobbs et. al., 2000) IgAN (Koselj-Kajtna, 2002) and hepatitis (Bates et. al., 1996;
Takahashi et. al., 2001).
A case of MGN was also documented in an arthritic patient receiving a gold containing
oral preparation called auronafin (Plaza et. al., 1982) as well as with a patient with
hemiretinal vein occlusion (Jorge et. al., 2002). MGN in the presence of neoplasms
suggests the presence of circulating antigen-antibody complexes formed by host





Ethical Approval has been granted by the Biomedical Research Ethics Committee
(Reference: H188/05) of the Nelson R Mandela School of Medicine, University of
KwaZulu-Natal. The Postgraduate Education Committee has also approved this study
(Reference: H188/05).
2.2 Patient and Control Recruitment
Patients were recruited from the provincial KwaZulu-Natal Kidney Transplant register
and KwaZulu-Natal Kidney Transplant waiting list as well as the outpatient list from the
Renal Clinic at Inkosi Albert Luthuli Central Hospital (IALCH). Inclusion criteria: all
adults patients from the 1970's to the 2000's with appropriate diagnosis. All patients
with unconfirmed diagnosis were excluded from the study. Patients were diagnosed by
histology.
Patients were educated verbally about the study, an information document describing the
study was issued and informed consent was obtained. Where applicable, a translator was
utilized. Patients were not forced to participate in the study.
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Controls were selected from the donor population on the kidney transplant list from the
1970's to present. These were cadaver (some of which death was due to gunshot
wounds) as well as living (friends, relatives) donors. The control population was
extensively studied. They present no evidence of renal disease. Biopsy was not done on
the control population as it is not ethical to biopsy patients with no evidence of renal
disease. The average age of the donor was 31 years. Males and females contributed
equally to the donor pool.
2.3 Sample Size
2.3.1 Patient Sample Size
This study was divided into three parts viz. Part A, Part B and Part C.
Part A was a screening study and it involved finding associations between HLA and
Hypertension in renal patients in the TUN setting.
Part B involved finding associations between HLA and three glomenilar diseases viz.
IgAN, FSGS and MGN. Certain patients in this study present with MGN secondary to
autoimmune diseases such as SLE.
Part C aimed to investigate if the presence or absence of certain HLA loci are responsible
for the African population's decreased susceptibility to IgAN.
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2.3.1.1 Part A Sample Size
The hypertensive Indian population comprised 93 patients, the African hypertensive
population comprised 71 patients and the White hypertensive population comprised 12
patients. Diagnosis of hypertension in these patients is presumptive and it cannot be
excluded that the hypertension could be secondary to underlying renal diseases.
2.3.1.2 Part B Sample Size
Initially 30 patients from each disease were proposed to be recruited each with equal
frequency from the African, Indian and White populations. Due to insufficient numbers,
IgAN, MGN and FSGS were grouped as glomerulonephritides. All patients were
diagnosed by biopsy.
The African population contained 0 IgAN patients and 24 patients with
glomerulonephritides. Patients with glomerulonephritides included 9 FSGS, 6 MGN and
9 NS with no known aetiology.
Sixty-two Indian patients were recruited. Indian patients with glomerulonephritides
comprised of 14 IgAN, 10 FSGS, 14 MGN, 5 MCGN, 1 immune complex GN and 18 NS
with no known aetiology.
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The White population encompassed 12 individuals with glomerulonephritides. White
patients with glomerulonephritides included 3 IgAN, 3 MCGN, 3 MGN, 1 FSGS and 2
NS with unknown aetiology.
The total patient sample size is thus 98 encompassing 24 African patients, 62 Indian
patients and 12 White patients.
2.3.1.3 Part C Sample Size
Part C comprised 201 African, 436 Indian and 290 White Individuals (Explained in
Chapter 2.7).
2.3.2 Control Sample Size
The total control population comprised 484 apparently healthy individuals from the donor
list. Of these individuals, 67 are African (See discussion); 187 are Indian and 230 are
White.
2.4 Sample Collection
After obtaining the patients consent, venous blood was collected in vacutainers
containing EDTA (purple caps) during their routine check up.
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2.5 Part A Method
This is a retrospective study. The transplant waiting list and the transplant register with
records dating back to the 1970's were studied. Ninety-three Indian, 71 African and 12
White hypertensive patients were selected. The HLA-A, -B and -DR loci were analyzed
and statistics was performed by the method described in Chapter 2.8.
2.6 Part B Method
2.6.1 DNA Extraction
DNA was extracted by means of the Qiagen QIAmp® DNA Blood Midi Kit (Southern
Cross Biotechnology, Cape Town) according to manufacturer's instructions. A volume
of lml blood was used in the extraction.
2.6.2 DNA Quantification
DNA was quantified by the NanoDrop® ND 1000 spectrophotometer. The concentration
of the quantified DNA was between 37.65-148.38 ng/i.d.
2.6.3 DNA Amplification
2.6.3.1 Principle of Procedure
The Dynal RELITM SSO HLA Typing Kits are based on the following three procedures.
The First is DNA amplification by a Polymerase Chain Reaction (PCR) where the DNA
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is multiplied exponentially by a chain reaction. This is explained in detail by Mullis and
Faloona (1987).
The second step is hybridization of the PCR products onto a nylon strip containing a
collection of fixed, Sequence Specific Oligonucleotide (SSO) probes which bind to
denatured biotin-labelled amplicons derived from the first step. The final step is
colorometric detection using streptavidin-horseradish peroxidase (SA-HRP). These
principles are fully explained by Saiki et. al. (1989).
2.6.3.2 Procedure
The quantified DNA was thereafter diluted to a concentration of 15ng4t1 (See Appendix)
with Qiagen nuclease-free H2O (Southern Cross Biotechnology, Cape Town).
For the HLA-A, -B and -DR loci, the sample DNA together with a positive control
(provided in kit) as well as a negative control (nuclease-free water) was amplified using
the Dynal RLLITM SSO HLA-A, -B and -DR Typing Kits (Southern Cross
Biotechnology, Cape Town) according to manufacturer's instructions.
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Probes were hybridized onto strips with the Dynal RELITM SSO Strip Detection Reagent
Kit (Southern Cross Biotechnology, Cape Town) according to manufacturer's
instructions. Time and temperature are pertinent during these steps. Positive probes
were visualized as blue bands on strips (Figure 2.1).
Figure 2.2 Transparent HLA-A locus template.
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2.6.5 Allele Detection
After probe hybridization, strips (e.g. Figure 2.1) were aligned onto a transparent
template which is provided with the kit (e.g. Figure 2.2) and analyzed according to
manufacturer's instructions. Exon 2 and Exon 3 are examined to determine the alleles
present. Bands 19, 42 and 43 are control probes on Figure 2.2 and appear as distinct
bands. Bands appearing on the negative control strip indicate cross contamination. Each
locus has a unique template with unique control probes.
Two methods of allele detection were employed to ensure accuracy. The Dynal Biotech
Pattern Matching Program (PMP) 5.41 was used to interpret the results. The first is an
automatic method where strips were placed on a metal template and scanned onto the
computer using a Hewlett-Packard (hp) scanjet 3670 scanner. The alleles were
automatically detected using the above-mentioned program.  The manual method
involved clicking the positive probes (blue bands) on a virtual strip present on the
computer program. Once all the positive probes are clicked on the strip, the computer
detects the allele/s present.
2.7 Part C Method
Part C involved the combination of both the diseased and donor populations from the
transplant register and waiting list as well as the Part B patient population. The
haplotypes of the individuals were analyzed and compared. Statistics was employed for
the HLA-A30, HLA-A29. HLA-A34, HLA-B42, HLA-B70, HLA-B58 and HLA-DR11
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loci between the African and Indian and African and White populations in attempt to
investigate a possible reason underlying the protection of the African population from
IgAN. These particular loci were selected as they are present in far greater amounts in
the African population than the Indian and White populations. These alleles were
therefore analyzed as it was presumed that they might contribute to the African
population's "immunity" to IgAN.
2.8 Statistical Analysis
Statistics was performed using the Graphpad InStat2TM statistical program. Due to the
small numbers for comparison, the frequency distribution of the HLA-A, -B and -DR loci
in hypertensives, renal patients and normal apparently healthy controls were compared
with a two-tailed Fisher's exact test with Yates' Continuity correction. The Relative risk
was calculated. The P values were corrected (Pa) by the following equation:
Pc= 1-(1-P)
n
Where n is the number of alleles tested for at each locus. P values in text are uncorrected
unless indicated by Pc . P values were corrected for 16 HLA-A, 15 HLA-B and 10 HLA-




3.1 PART A: Hypertension in Renal Disease in KwaZulu-Natal
Indian Population
An association was noted between HLA-A28 and the Indian control population (P=
0.0330; RR=0.3; 95% CI: 0.1245-0.9820) (Table 3.1.1). A relative risk less than one
indicated a decreased risk however when corrected for P, Pc= 0.99 hence there was no
association between hypertension and HLA-A28.
Table 3.1.1 also showed an association between HLA-A33 and hypertension (P= 0.0146;
RR=2.6; 95% CI: 1.029-5.416). When corrected, P,= 0.99.
Table 3.1.2 showed associations between HLA-B38 (P= 0.0165; RR=10.054; 95% CI:
1.191-84.865), HLA-B40 (P<0.0001; RR=32.2; 95% CI: 4.330-239.01) and HLA-B52
(P= 0.0290; RR=0.4399; 95% CI: 0.2018-0.9588) however when corrected for P, only
HLA-B40 (Pc<0.05) was significantly associated with hypertension. Therefore HLA-
B40 is a possible susceptibility marker for hypertension in Indian patients carrying the
allele.
Associations between Blank HLA-DR alleles (explained in Chapter1.1.2.2) and the
control population (P= 0.0101; RR=0; 95% CI: —.0-.0) as well as HLA-DR2 (P= 0.0020;
RR=0.2873; 95% CI: 0.1164-0.7091) and the hypertensive population are indicated by
Table 3.1.3. Again when corrected for P, both loci showed no significant association.
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Table 3.1.1 HLA-A antigen frequencies in Indian hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 374 n = 186
Blank 2 0.53 0 0.00 0.0 1.0000
Al 46 12.30 26 13.98 1.1 0.5635
A2 78 20.86 34 18.28 0.9 0.4389
A3 18 4.81 15 8.06 1.7 0.1193
A4 1 0.27 1 0.54 2.0 1.0000
All 60 16.04 25 13.44 0.8 0.4096
A23 2 0.53 0 0.00 0.0 1.0000
A24 83 22.19 46 24.73 1.1 0.4468
A26 16 4.28 8 4.30 1.0 1.0000
A28 23 6.15 4 2.15 0.3 0.0330*
A29 3 0.80 0 0.00 0.0 0.5532
A30 6 1.60 3 1.61 1.0 1.0000
A31 15 4.01 5 2.69 0.7 0.4721
A32 8 2.14 4 2.15 1.0 1.0000
A33 11 2.94 14 7.53 2.6 0.0146*
A34 1 0.27 1 5.00 2.0 1.0000
A68 1 0.27 0 0.00 0.0 1.0000
* indicates statistical significance.
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Table 3.1.2 HLA-B antigen frequencies in Indian hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 374 OA n = 186
Blank 2 0.53 0 0.00 0.0 1.0000
B I 3 0.80 0 0.00 0.0 0.5532
B4 2 0.53 0 0.00 0.0 1.0000
B7 28 7.49 12 6.62 0.9 0.7191
B8 11 2.94 8 4.41 1.5 0.4512
B 13 15 4.01 3 2.21 0.4 0.1945
B14 I 0.27 0 0.00 0.0 1.0000
B15 4 1.07 6 2.21 3.0 0.0879
B16 5 1.34 0 0.00 0.0 0.1737
B 17 I 0.27 0 0.00 0.0 1.0000
BI8 2 0.53 6 2.21 6.0 0.0179
B22 4 1.07 0 0.00 0.0 0.3053
B27 2 0.53 2 0.74 2.0 0.6021
B35 44 11.76 15 10.29 0.7 0.1648
B37 14 3.74 4 2.21 0.3 0.0152
B38 1 0.27 5 2.21 10.1 0.0165*
B39 4 1.07 0 0.00 0.0 0.3053
B40 l 0.27 16 6.62 32.2 < 0.0001*
B44 23 6.15 16 18.09 1.4 0.2757
B48 0 0.00 2 0.74 00 0.1095
B49 4 1.07 5 2.21 2.5 0,1641
B50 0 0.00 2 0.74 00 0.1095
B51 46 12.30 24 13.97 1.0 0.8837
B52 32 8.56 7 4.41 0.4 0.0290*
B53 2 0.53 1 0.74 1.0 1.0000
B55 4 1.07 0 0.00 0.0 0.3053
B57 29 7.75 19 10.29 1.3 0.3159
B58 8 2.14 5 2.94 1.3 0.7649
B60 17 4.55 6 3.68 0.7 0.4989
B61 42 11.23 18 10.29 0.9 0.6433
B62 15 4.01 3 1.47 0.4 0.1941
B63 I 0.27 0 0.00 0.0 1.0000
B65 1 0.27 0 0.00 0.0 1.0000
B70 6 1.60 1 0.74 0.3 0.4309
* indicates statistical significance.
89
Table 3.1.3 HLA-DR antigen frequencies in Indian hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 374 % n =186 %
Blank 12 3.21 0 0.00 0.0 0.0101*
DRI 8 2.14 6 3.68 1.5 0.5611
DR2 35 9.36 5 3.68 0.3 0.0020*
DR3 38 10.16 12 7.35 0.6 0.1390
DR4 50 13.37 25 13.97 1.0 1.0000
DR5 13 3.48 2 1.47 0.3 0.1559
DR6 6 1.60 1 0.74 0.3 0.4309
DR7 56 14.97 35 18.38 1.3 0.2293
DR8 7 1.87 6 2.94 1.7 0.3684
DR9 4 1.07 2 0.74 1.0 1.0000
DRIO 19 5.08 12 5.88 1.3 0.5454
DR11 9 2.41 10 4.41 1.1 1.0000
DR12 10 2.67 6 2.94 1.2 0.7860
DR13 23 6.15 13 6.62 1.1 0.7072
DR14 33 8.82 16 7.35 1.0 1.0000
DRI5 51 13.64 35 19.85 1.4 0.0985
* indicates statistical significance.
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African Population
An association between HLA-A68 (P=0.0269; RR=3.8; 95% CI: 1.114-12.793) and HLA-
A74 (P=0.0026; RR=6.6; 95% CI: 1.559-27.988) with hypertension in Africans is shown in
Table 3.1.4. When corrected for P, no association was detected.
An association between HLA-B15 (P<0.0001; RR=9.4; 95% CI: 2.292-38.847) as well as
HLA-B44 (P=0.0075; RR=2.6; 95% CI: 1.241-5.424) and hypertension is shown by Table
3.1.5. When corrected for P, only HLA-B15 maintained significance (P c<0.02).
An association between HLA-DR13 (P=0.0193; RR=1.8; 95% CI: 1.106-3.023) and African
hypertensive patients is noted before correction (Table 3.1.6). After correction, Pc= 0.99.
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Table 3.1.4 HLA-A antigen frequencies in African hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 134 % n = 142 "Vo
Al 4 2.99 6 4.23 1.4 0.7456
A2 26 19.40 25 17.61 0.9 0.7255
A3 8 5.97 10 7.04 1.2 0.8029
Al 1 1 0.75 1 0.70 0.9 1.0000
A23 14 10.45 18 12.68 1.2 0.5525
A24 4 2.99 3 2.11 0.7 0.7127
A26 5 3.73 I 0.70 0.2 0.1081
A28 12 8.96 II 7.75 0.9 0.8202
A29 13 9.70 6 4.23 0.4 0.0822
A30 25 18.66 19 13.38 0.7 0.2045
A3I I 0.75 1 0.70 0.9 1.0000
A32 2 1.49 I 0.70 1.9 1.0000
A34 1 1 8.21 11 7.75 0.9 1.0000
A43 2 1.49 1 0.70 1.9 1.0000
A66 0 0.00 2 1.41 .. 0.4968
A68 3 2.24 12 8.45 3.8 0.0269*
A74 2 1.49 14 9.86 6.6 0.0026*
A80 1 0.75 0 0.00 0.0 0.4855
* indicates statistical significance.
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Table 3.1.5 HLA-B antigen frequencies in African hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 134 % n = 142 %
Bu 1 0.75 0 0.00 0.0 0.4855
B7 9 6.72 13 9.15 0.6 0.3357
B8 12 8.96 8 5.63 0.6 0.3357
B12 1 0.75 1 0.70 0.9 1.0000
B13 2 1.49 0 0.00 0.0 0.2339
B14 8 5.87 12 8.45 1.4 0.4733
B15 2 1.49 20 14.08 9.4 < 0.0001*
B 16 0 0.00 1 0.70 00 1.0000
B 17 2 1.49 0 0.00 0.0 0.2339
B18 4 2.99 3 2.11 0.7 0.7127
B27 1 0.75 0 0.00 0.0 0.4855
B35 8 5.91 6 4.23 0.7 0.5790
B36 1 0.75 0 0.00 0.0 0.4855
B39 I 0.75 0 0.00 0.0 0.4855
B41 2 1.49 3 2.11 1.6 0.6711
B42 16 11.94 15 10.56 0.9 0.8386
B44 8 5.97 22 15.49 2.6 0.0075*
B45 0 0.00 2 1.41 0. 0.4968
B49 1 0.75 0 0.00 0.0 0.4855
B50 0 0.00 2 1.41 00 0.4968
B51 4 2.99 1 0.70 0.2 0.1989
B57 13 9.70 9 6.34 0.7 0.3539
B58 18 13.43 9 6.34 0.5 0.0523
B61 0 0.00 1 0.70 00 1.0000
B62 2 1.49 1 0.70 1.9 1.0000
B65 0 0.00 1 0.70 0. 1.0000
B70 17 12.69 10 7.04 0.6 0.1324
B81 1 0.75 2 1.41 1.9 1.0000
* indicates statistical significance.
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Table 3.1.6 HLA-DR antigen frequencies in African hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 134 % n = 142 %
Blank 2 1.47 0 0.00 0.0 0.2339
DR1 1 0.74 3 2.11 2.8 0.6201
DR2 2 1.47 3 2.11 1.4 1.0000
DR3 24 18.38 26 18.31 1.0 1.0000
DR4 8 5.88 8 5.63 0.9 1.0000
DR5 5 3.68 1 0.70 0.2 0.1081
DR6 4 2.94 1 0.70 0.2 0.1989
DR7 16 11.76 13 9.15 0.8 0.5313
DR8 5 3.68 3 2.11 0.6 0.4842
DR9 2 1.47 1 0.70 1.9 1.0000
DRIO 1 0.74 4 2.82 3.8 0.3669
DR11 24 18.38 24 16.90 0.9 0.8590
DR12 4 2.94 2 1.41 0.5 0.4313
DR13 16 11.76 31 21.83 1.8 0.0193*
DR14 1 0.74 3 2.11 2.8 0.6201
DR15 18 13.24 19 13.38 1.0 1.0000
DR16 1 0.74 0 0.00 0.0 0.4855
* indicates statistical significance.
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White Population
There is an association between HLA-A2 and the control population (P=0.0317; RR=0.4;
95% CI: 0.1566-1.125) as shown by Table 3.1.7. An association was also noted between
HLA-A31 and the hypertensive population (P=0.0413; RR=7.7; 95% CI: 1.653-35.330).
When corrected, Pc= 0.99 for both loci. No significant conclusion can be made.
Table 3.1.8 showed an association between HLA-B42 and hypertension (P=0.0066;
RR=38.3; 95% CI: 3.730-393.92) but Pc=0.95.
An association is noted between Blank HLA-DR alleles and the control population
(P=0.0401; RR=0; 95% CI: --.0-00) (Table 3.1.9). An association is shown between HLA-
DR3 and hypertension (P=0.0032; RR=2.7; 95% CI: 1.728-4.340). Corrected P values
indicated no association. P c=0.86 and 0.79 respectively.
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Table 3.1.7 HLA-A antigen frequencies in White hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 460 "A n = 24 "A
Blank 2 0.43 0 0.00 0.0 1.0000
Al 72 15.65 6 25.00 1.6 0.2090
A2 137 29.78 3 13.00 0.4 0.0317*
A3 68 14.78 3 13.00 0.8 1.0000
A 1 I 24 5.22 I 4.20 0.8 1.0000
A23 13 2.83 0 0.00 0.0 1.0000
A24 39 8.48 1 4.20 0.5 0.6963
A25 6 1.30 2 8.00 6.4 0.0535
A26 21 4.57 I 4.20 0.0 0.6069
A28 20 4.35 0 0.00 0.0 0.6061
A29 15 3.26 2 8.00 2.6 0.2022
A30 9 1.96 2 8.00 4.3 0.0967
A31 5 1.09 2 8.00 7.7 0.0413*
A32 21 4.57 1 4.20 0.9 1.0000
A33 4 0.87 0 0.00 0.0 1.0000
A34 1 0.22 0 0.00 0.0 1.0000
A36 1 0.22 0 0.00 0.0 1.0000
A68 1 0.22 0 0.00 0.0 1.0000
A82 1 0.22 0 0.00 0.0 1.0000
* indicates statistical significance.
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Table 3.1.8 HLA-B antigen frequencies in White hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 460 % n = 24 %
B3 1 0.22 1 4.00 19.2 0.0969
B5 1 0.22 0 0.00 0.0 1.0000
B7 82 17.83 3 12.50 0.7 0.5485
B8 59 12.83 3 12.50 1.0 1.0000
B11 1 0.22 0 0.00 0.0 1.0000
B12 3 0.65 0 0.00 0.0 1.0000
B13 6 1.30 1 4.00 3.2 0.3028
B14 24 5.22 0 0.00 0.0 0.6149
B15 15 3.26 1 4.00 1.3 0.5686
B16 2 0.43 0 0.00 0.0 1.0000
B17 3 0.65 0 0.00 0.0 1.0000
B18 13 2.83 1 4.00 1.5 0.5193
B22 1 0.22 0 0.00 0.0 1.0000
B27 15 3.26 0 0.00 0.0 1.0000
B29 1 0.22 0 0.00 0.0 1.0000
B35 34 7.39 2 8.00 1.1 0.6948
B37 4 0.87 0 0.00 0.0 1.0000
B38 7 1.52 1 4.00 2.7 0.3384
B39 9 1.96 0 0.00 0.0 1.0000
B40 7 1.52 1 4.00 2.7 0.3384
B41 2 0.43 0 0.00 0.0 1.0000
B42 1 0.22 2 8.00 38.3 0.0066*
B44 46 10.00 1 4.00 0.4 0.4700
B45 I 0.22 0 0.00 0.0 1.0000
B47 2 0.43 0 0.00 0.0 1.0000
B48 I 0.22 0 0.00 0.0 1.0000
B49 2 0.43 0 0.00 0.0 1.0000
B50 4 0.87 0 0.00 0.0 1.0000
B51 15 3.26 1 4.00 1.3 0.5686
B52 3 0.65 0 0.00 0.0 1.0000
B55 3 0.65 0 0.00 0.0 1.0000
B56 4 0.87 0 0.00 0.0 1.0000
B57 11 2.39 1 4.00 1.7 0.4647
B58 10 2.17 0 0.00 0.0 1.0000
B60 20 4.35 1 4.00 1.0 1.0000
B61 10 2.17 1 4.00 1.9 0.4354
B62 28 6.09 2 8.00 1.4 0.6484
B63 3 0.65 0 0.00 0.0 1.0000
B65 I 0.22 0 0.00 0.0 1.0000
B70 3 0.65 I 4.00 6.4 0.1851
B7I I 0.22 0 0.00 0.0 1.0000
B75 I 0.22 0 0,00 0.0 1.0000
* indicates statistical significance.
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Table 3.1.9 HLA-DR antigen frequencies in White hypertensive patients and controls in KwaZulu-Natal.
Controls Patients
Relative Risk
p valuen = 460 % n = 24 %
Blank 62 13.48 0 0.00 0.0 0.0401*
DR I 36 7.83 0 0.00 0.0 0.2225
DR2 16 3.48 0 0.00 0.0 1.0000
DR3 56 12.17 8 33.00 2.7 0.0032*
DR4 69 15.00 5 20.00 1.4 0.5206
DR5 6 1.30 0 0.00 0.0 1.0000
DR6 10 2.17 0 0.00 0.0 1.0000
DR7 44 9.57 1 4.00 0.4 0.7017
DR8 13 2.83 0 0.00 0.0 1.0000
DR9 9 1.96 0 0.00 0.0 1.0000
DR 1 0 7 1.52 1 4.00 2.7 0.3384
DR 1 1 24 5.22 3 12.50 0.2 0.1374
DR12 10 2.17 1 4.00 1.9 0.4354
DR13 35 7.61 1 4.00 0.5 1.0000
DR14 9 1.95 0 0.00 0.0 1.0000
DR15 49 10.65 4 17.00 1.6 0.3020
DR16 5 1.09 0 0.00 0.0 1.0000
* indicates statistical significance.
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3.2 PART B: HLA allele frequencies in Renal Disease in KwaZulu-Natal
3.2.1 Indian Population
An association is shown between HLA-A33 (P<0.0001; RR-4.4; 95% CI: 2.152-8.942) as
well as HLA-A68 (P=0.0003; RR-21.1; 95% CI: 2.648-168.33) with glomerulonephritides
in the Indian A locus (Table 3.2.1.1). When corrected, P c<0.049 for HLA-A33 and 0.14 for
HLA-A68.
The distribution of HLA-DR alleles in glomerulonephritides patients vs. controls is shown in
Table 3.2.1.2. An association is noted between Blank HLA-DR alleles and the control
population (P=- 0.0413; RR=0; 95% CI: —.0-0.) but P c=0.99 indicating no significance.
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p valuen = 374 % n =124 %
Blank 2 0.53 0 0.00 0.0 1.0000
Al 46 12.30 13 13.54 0.9 0.6092
A2 78 20.86 21 21.88 0.8 0.2977
A3 18 4.81 6 6.25 1.0 1.0000
A4 I 0.27 0 0.00 0.0 1.0000
All 60 16.04 20 20.83 1.0 1.0000
A23 2 0.53 0 0.00 0.0 1.0000
A24 83 22.19 22 22.92 0.8 0.2380
A26 16 4.28 3 3.13 0.6 0.4197
A28 23 6.15 8 8.33 1.0 1.0000
A29 3 0.80 1 1.04 1.0 1.0000
A30 6 1.60 0 0.00 0.0 0.3412
A3 I 15 4.01 4 4.17 0.8 0.7896
A32 8 2.14 3 3.13 1.1 1.0000
A33 11 2.94 16 16.67 4.4 < 0.0001*
A34 I 0.27 0 0.00 0.0 1.0000
A68 I 0.27 7 7.29 21.1 0.0003*
* indicates statistical significance.
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p valuen = 374 n =124
Blank 12 3.21 0 0.00 0.0 0.0413*
DR1 8 2.14 5 4.03 1.9 0.3199
DR2 35 9.36 8 6.45 0.7 0.3378
DR3 38 10.16 11 8.87 0.9 0.7162
DR4 50 13.37 18 14.52 1.1 0.7437
DR5 13 3.48 6 4.84 1.4 0.5805
DR6 6 1.60 5 4.03 2.5 0.1478
DR7 56 14.97 24 19.35 1.3 0.2121
DR8 7 1.87 3 2.42 1.3 0.7134
DR9 4 1.07 2 1.61 1.5 0.6407
DRIO 19 5.08 7 5.65 1.1 0.8122
DR11 9 2.41 6 4.84 2.0 0.2144
DR12 10 2.67 1 0.81 0.3 0.3009
DR 13 23 6.15 4 3.23 0.5 0.1713
DRI4 33 8.82 7 5.65 0.6 0.3185
DAIS 51 13.64 17 13.71 1.0 1.0000
* indicates statistical significance.
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3.2.2 African Population
The distribution of the various HLA-A locus alleles is shown between the African
glomerulonephritides and control populations (Table 3.2.2.1). An association between HLA-
A2 (P=0.0010; RR=9.8; 95% CI: 2.178-43.837) as well as HLA-A68 (P=0.0448; RR=3.4;
95% CI: 1.070-12.559) is noted in the glomerulonephritides patient population but when
corrected Pc=0.17 and 0.99 respectively.
The African HLA-DR locus showed no associations with the glomerulonephritides patient
and control populations (Table 3.2.2.2).
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p valuen = 134 % n = 48 %
AI 4 2.99 2 4.17 1.4 0.6523
A2 26 19.40 7 14.58 9.8 0.0010*
A3 8 5.97 I 2.08 0.3 0.4360
All 1 0.75 0 0.00 0.0 1.0000
A23 14 10.45 5 10.42 1.0 1.0000
A24 4 2.99 1 2.08 0.7 1.0000
A26 5 3.73 0 0.00 0.0 0.3213
A28 12 8.96 2 4.17 0.5 0.3397
A29 13 9.70 5 10.42 1.1 1.0000
A30 25 18.66 5 10.42 0.6 0.2059
A3I 1 0.75 I 2.08 0.5 2.7920
A32 2 1.49 0 0.00 0.0 1.0000
A34 II 8.21 2 4.17 0.5 0.5012
A36 0 0.00 I 2.08 .0 0.2637
A43 2 1.49 2 4.17 2.8 0.2830
A68 3 2.24 II 22.92 3.7 0.0448*
A74 2 1.49 3 6.25 2.1 0.3748
A80 1 0.75 0 0.00 0.0 1.0000
* indicates statistical significance.
103




p valuen = 134 % n = 48 %
Blank 2 1.47 0 0.00 0.0 1.0000
DR1 I 0.74 0 0.00 0.0 1.0000
DR2 2 1.47 1 2.08 1.4 1.0000
DR3 24 18.38 I1 22.92 1.3 0.4655
DR4 8 5.88 3 6.25 1.0 1.0000
DR5 5 3.68 0 0.00 0.0 0.5698
DR6 4 2.94 0 0.00 0.0 0.3201
DR7 16 11.76 5 10.42 0.9 1.0000
DR8 5 3.68 I 2.08 0.6 1.0000
DR9 2 1.47 0 0.00 0.0 1.0000
DR I 0 1 0.74 0 0.00 0.0 1.0000
DR I 1 24 18.38 12 25.00 1.4 0.2353
DRI 2 4 2.94 0 0.00 0.0 0.3201
DR13 16 11.76 7 14.58 1.2 0.5691
DRI 4 1 0.74 2 4.17 5.6 0.1689
DR15 18 13.24 6 12.50 0.9 1.0000
DR16 1 0.74 0 0.00 0.0 1.0000
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3.2.3 White Population (glomerulonephritides)
A similar distribution between the HLA-A locus alleles of White glomerulonephritides
patients and controls is shown by Table 3.2.3.1. No increased frequencies and no
associations were noted.
HLA-B locus alleles of White glomerulonephritides patients and controls are presented in
Table 3.2.3.2. HLA-B18 (P=0.0363; RR-4.4; 95% CI: 1.550-14.687); HLA-B27 (P=0.0499;
RR-3.8; 95% CI: 1.282-11.465) and HLA-B40 (P=0.0093; RR=8.2; 95% CI: 2.420-27.878)
are show associations in the patient population but when corrected for P, no significance was
noted.
An association is noted between Blank HLA-DR alleles in the control population (P=0.0401;
RR-0.0; 95% CI: as shown by Table 3.2.3.3. HLA-DR3 (P=0.0154; RR=2.4; 95%
CI: 1.410-4.070) and HLA-DR16 (P=0.0413; RR=7.7; 95% CI: 1.653-35.330) are associated
with glomerulonephritides but when corrected for P, Pc=0.99 for all three loci hence no
significant association was observed.
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p valuen = 460 °A n = 24 %
Blank 2 0.43 0 0.00 0.0 1.0000
Al 72 15.65 7 29.20 1.9 0.0627
A2 137 29.78 5 20.80 0.7 0.2420
A3 68 14.78 4 16.60 1.1 0.7539
All 24 5.22 I 4.20 0.8 1.0000
A23 13 2.83 2 8.30 2.9 0.1650
A24 39 8.48 3 12.50 1.5 0.4421
A25 6 1.30 I 4.20 3.2 0.3028
A26 21 4.57 0 0.00 0.0 0.6069
A28 20 4.35 0 0.00 0.0 0.6061
A29 15 3.26 0 0.00 0.0 1.0000
A30 9 1.96 0 0.00 0.0 1.0000
A31 5 1.09 I 4.20 3.8 0.2654
A32 21 4.57 0 0.00 0.0 0.6069
A33 4 0.87 0 0.00 0.0 1.0000
A34 1 0.22 0 0.00 0.0 1.0000
A36 I 0.22 0 0.00 0.0 1.0000
A68 I 0.22 0 0.00 0.0 1.0000
A82 I 0.22 0 0.00 0.0 1.0000
* indicates statistical significance.
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p valuen = 460 % n = 24 %
B3 1 0.22 0 0.00 0.0 1.0000
B5 1 0.22 0 0.00 0.0 1.0000
B7 82 17.83 3 12.50 0.7 0.5485
B8 59 12.83 5 20.80 1.6 0.3104
B11 1 0.22 0 0.00 0.0 1.0000
B12 3 0.65 0 0.00 0.0 1.0000
B 13 6 1.30 0 0.00 0.0 1.0000
B 14 24 5.22 0 0.00 0.0 0.6149
B15 15 3.26 I 4.20 1.3 0.5686
B 16 2 0.43 1 4.20 9.6 0.1421
B 17 3 0.65 0 0.00 0.0 1.0000
B18 13 2.83 3 12.50 4.4 0.0363*
B22 1 0.22 0 0.00 0.0 1.0000
B27 15 3.26 3 12.50 3.8 0.0499*
B29 1 0.22 0 0.00 0.0 1.0000
B35 34 7.39 1 4.20 0.6 1.0000
B37 4 0.87 1 4.20 4.8 0.2262
B38 7 1.52 0 0.00 0.0 1.0000
B39 9 1.96 2 8.30 4.3 0.0967
B40 7 1.52 3 12.50 8.2 0.0093*
B41 2 0.43 0 0.00 0.0 1.0000
B42 1 0.22 0 0.00 0.0 1.0000
B44 46 10.00 0 0.00 0.0 0.1299
B45 1 0.22 0 0.00 0.0 1.0000
B47 2 0.43 0 0.00 0.0 1.0000
B48 I 0.22 0 0.00 0.0 1.0000
B49 2 0.43 0 0.00 0.0 1.0000
B50 4 0.87 0 0.00 0.0 1.0000
B51 15 3.26 0 0.00 0.0 1.0000
B52 3 0.65 0 0.00 0.0 1.0000
B55 3 0.65 0 0.00 0.0 1.0000
B56 4 0.87 0 0.00 0.0 1.0000
B57 11 2.39 0 0.00 0.0 1.0000
B58 10 2.17 0 0.00 0.0 1.0000
B60 20 4.35 0 0.00 0.0 0.6061
B61 10 2.17 0 0.00 0.0 1.0000
B62 28 6.09 0 0.00 0.0 0.3698
B63 3 0.65 1 4.20 6.4 0.1851
B65 1 0.22 0 0.00 0.0 1.0000
B70 3 0.65 0 0.00 0.0 1.0000
B71 1 0.22 0 0.00 0.0 1.0000
B75 1 0.22 0 0.00 0.0 1.0000
* indicates statistical significance.
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p valuen = 460 n = 24
Blank 62 13.48 0 0.00 0.0 0.0401*
DRI 36 7.83 3 12.50 0.2 0.4163
DR2 16 3.48 I 4.20 1.2 0.5915
DR3 56 12.17 7 29.00 2.4 0.0154*
DR4 69 15.00 4 16.70 1.1 0.7569
DRS 6 1.30 0 0.00 0.0 1.0000
DR6 10 2.17 0 0.00 0.0 1.0000
DR7 44 9.57 1 4.20 0.4 0.7017
DR8 13 2.83 I 4.20 1.5 0.5193
DR9 9 1.96 0 0.00 0.0 1.0000
DRIO 7 1.52 0 0.00 0.0 1.0000
DR I I 24 5.22 3 12.50 2.4 0.1374
DRI2 10 2.17 0 0.00 0.0 1.0000
DRI3 35 7.61 I 4.20 0.5 1.0000
DRI4 9 1.95 0 0.00 0.0 1.0000
DRI5 49 10.65 1 4.20 0.4 0.4683
DR 16 5 1.09 2 8.30 7.7 0.0413*
* indicates statistical significance.
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3.2.4 Combined Race Groups
Race groups were combined to determine if race was independent of GD.
The HLA-A locus of combined Race groups (Table 3.2.4.1) show an association between
HLA-A2 and the control population (P= 0.0052; RR=0.68; 95% CI: 0.5106-0.9143) but
when corrected for P, Pc=0.99. Another association was found between HLA-A74 and Race
combined glomerulonephritides patients (P= 0.0350; RR=7.5; 95% CI: 0.7186-35.372). No
significance was maintained when corrected for P (Pc=1). Two associations were noted
between HLA-A33 (P<0.0001; RR=5.3; 95% CI: 2.724-10.401) and HLA-A68 (P<0.0001;
RR=17.96; 95% CI: 6.832-47.232) and the Race combined glomerulonephritides patients.
When corrected for P, both loci showed no significance (Pc=0.11)
The Race combined HLA-DR locus showed an association between Blank HLA-DR alleles
and the Race combined control population (P<0.0001; RR=0; 95% Cl: —00-09) but P c=0.11.
Another association was found between HLA-DR11 (P=0.0137; RR=1.8; 95% CI: 1.172-
2.884) and the Race combined glomerulonephritides patients. When corrected for P
however, no association was maintained (Pc=0.99).
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p valuen = 968 % n =194 %
Blank 4 0.41 0 0.00 0.00 1.0000
Al 122 12.60 22 11.34 0.90 0.6993
A2 241 24.90 33 17.01 0.68 0.0052*
A3 94 9.71 II 5.67 0.58 0.0611
A4 1 0.10 I 0.52 4.99 0.3063
All 85 8.78 22 11.34 1.29 0.2513
A23 29 3.00 8 4.12 1.38 0.3698
A24 126 13.02 24 12.37 0.95 0.8989
A25 6 0.62 0 0.00 0.00 0.5960
A26 42 4,34 3 1.55 0.36 0.0623
A28 55 5.68 10 5.15 0.91 0.8612
A29 31 3.20 6 3.09 0.97 1.0000
A30 40 4.13 6 3.09 0.75 0.6797
A31 21 2.17 5 2.58 1.19 0.7868
A32 31 3.20 3 1.55 0.46 0.2430
A33 15 1.55 16 8.25 5.32 <0.0001*
A34 13 1.34 2 1.03 0.77 1.0000
A36 I 0.10 I 0.52 4.99 0.3063
A43 2 0.21 0 0.00 0.00 1.0000
A68 5 0.52 18 9.28 17.96 <0.0001 *
A74 2 0.21 3 1.55 7.49 0.0350*
A80 1 0.10 0 0.00 0.00 1.0000
A82 1 0.10 0 0.00 0.00 1.0000
* indicates statistical significance.
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p valuen = 968 % n =194 %
Blank 76 7.85 0 0.00 0.00 <0.0001*
DR1 45 4.65 8 4.12 0.89 0.8485
DR2 53 5.48 9 4.64 0.85 0.7210
DR3 118 12.19 29 14.95 1.23 0.2522
DR4 127 13.12 25 12.89 0.98 1.0000
DR5 24 2.48 6 3.09 1.25 0.6155
DR6 20 2.07 5 2.58 1.25 0.5894
DR7 116 11.98 30 15.46 1.29 0.1591
DR8 25 2.58 5 2.58 1.00 1.0000
DR9 15 1.55 2 1.03 0.67 0.7509
DRIO 27 2.79 7 3.61 1.29 0.4836
DR11 57 5.89 21 10.82 1.84 0.0137*
DR 12 24 2.48 1 0.52 0.21 0.1001
DR13 74 7.64 12 6.19 0.81 0.5329
DR14 43 4.44 9 4.64 1.04 0.8471
DR15 118 12.19 24 12.37 1.02 1.0000
DR16 6 0.62 1 0.52 0.83 1.0000
* indicates statistical significance.
3.3 Part C: The Rarity of IgAN In Africans
This section involved the comparison of the combination of alleles from both the diseased
and control populations of all race groups viz. African, Indian and White. Our KZN setting,
concurrent with other settings, has shown that IgAN is very rare or non-existent in the
African population. This is shown by Figure 3.3.1
The aim of this section was to investigate a possible underlying reason for the African race
group to be protective against IgAN.
In comparing the A locus alleles (Figure 3.3.2) of the three race groups, the following was
observed. Allele HLA-A30 was extremely significantly higher in the African population
when compared to the Indian and White populations. African vs. Indian (P<0.0001, RR=9.1,
95% CI: 5.230-15.977) and African vs. White (P<0.0001, RR=5.7, 95% CI: 3.315-9.715).
HLA-A29 was also significantly increased in the African vs. Indian (P<0.0001, RR=9.6,
95% CI: 4.770-19.486) and African vs. White (P<0.0001, RR=2.9, 95% CI: 1.740-4.785)
populations. Another A locus allele, HLA-A34 showed to be extremely significant in
Africans when compared to Indians (P<0.0001, RR=30.4, 95% CI: 7.303-126.28) and Whites
(P<0.0001, RR=20.2, 95% CI: 4.865-83.865).
The B locus (Figure 3.3.3) showed extremely significant increases in HLA-B42, HLA-B58
and HLA-B70 in the African population. HLA-B42, Africans vs. Indians (P<0.0001, RR=oo,
95% CI: —0.-00) and Africans vs. Whites (P<0.0001, RR=10.1, 95% CI: 4.375-23.312).
HLA-B58, Africans vs. Indians (P<0.0001, RR=4.7, 95% CI: 2.819-7.717) and Africans vs.
Whites (P<0.0001, RR=4.4, 95% CI: 2.482-7.881). HLA-B70, Africans vs. Indians
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(P<0.0001, RR-9.3, 95% CI: 4.784-18.185) and Africans vs. White (P<0.0001, RR=15.5,
95% CI: 5.655-42.537).
The DR locus (Figure 3.3.4) showed an extremely significant increase in HLA-DR1 1 in the
African population when compared to Indians (P<0.0001, RR=5.4, 95% CI: 3.623-7.903)
and Whites (P<0.0001, RR-6.1, 95% CI: 4.219-8.822).
P was not corrected intentionally. This was done because HLA loci were not compared to a
particular disease rather the aim of this part of the study was to observe whether the African
Race as a whole (diseased and normal) carried specific alleles that contributed to their
protection from IgAN. A different form of analysis was carried out therefore P was not
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This study is divided into three parts viz Part A, Part B and Part C.
The first part of this study deals with the association of the HLA antigens with
hypertension in three different KZN populations viz. African, Indian and White.
The clinical data of this study (not published) indicates a high prevalence of hypertension
in the KZN Indian population. In addition hypertension has been shown to be huge
problem in India (Gupta et. al.. 200) wherefrom South African Indians descend. When
compared between two different geographically separated Indian populations viz. North
Indian and South Indian, hypertension was shown to be more prevalent in the South
Indian population despite a lower fat and salt intake (Malhotra, 1970). Diet therefore
seemed to be independent of hypertension although the author suggested the influence of
dietary factors on blood physiology.
Although two different Indian populations were studied, both responded differently to
hypertension in spite of diet. This suggests that the geographic location might have an
influence due to environmental factors. This is concurrent with the HLA principle where
different populations in terms of race and geographic location respond differently to
diseases.
This study showed a significant association between HLA-B40 and hypertension in the
Indian population suggesting a possible disease susceptibility marker. A relative risk of
118
32.2 indicates that an Indian individual possessing the HLA-B40 allele will be 32.2 times
more likely to develop hypertension than a person lacking the HLA-B40 allele.
During the apartheid era, natives (as Africans were known) were forced into small areas
and the population increased by a ratio of 0.76 in a period of twenty years (Kuper, 1950).
This increase in population was due to interbreeding, which resulted in overcrowding,
poor socio-economic status and limited genetic diversity. Rural African men were
therefore forced to leave their families to tend to the farms and move to urban areas, a
process known as urbanization (Kothari and Mehta, 1984) in search of a 'better life'
where they had to tend to their own nutritional needs. This is a drastic change from their
healthy, low fat, low salt rural diets which did not comprise unhealthy processed foods.
An unhealthy diet gradually leads to obesity which is associated with hypertension.
Although a rural diet seems to be healthier, a stigma attached to African men in terms of
their ability to provide for their families results in rural African women having a greater
waist size (Puoane et. a/., 2002) hence being more susceptible to hypertension.
Unlike the inconsistency in the Indian population, hypertension seems to be constantly
prominent among the African race group in various populations (McClellan et. al., 1988;
Tierny et. al., 1989) and in spite of blood pressure control kidney function seems to
decline (Rostand et. al., 1989). In South Africa urbanization is said to increase the
prevalence of hypertension in the African population by 25% (Steyn et. al., 2001).
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This study shows an association between HLA-B15 and hypertension in the KZN African
population suggesting a possible disease susceptibility allele.  Although different
ethnicities these results correlate with a Swedish (Hilme et. al., 1993) as well as an
English population (Gudbrandsson et. al., 1980). A relative risk of 9.4 indicates that
KZN Africans with the HLA-B15 allele are 9.4 times more likely to develop
hypertension than Africans without the allele.
No significant association was found between HLA and hypertension in the White
population. This is due to a small sample size which makes it difficult to perform a
statistical test or reach significance. There are two possible factors contributing to the
small sample size.
The first could be due to diet. During the period of apartheid White South Africans had
the privilege of education and private health care. This posed as an advantage as the
White population were aware of what a healthy diet entailed although recently (post-
apartheid) educated White women were still shown to have smaller waists than rural
African women (Puoane et. al., 2002). Waist size is a determinant of abdominal obesity
which predisposes an individual to hypertension hence the smaller the waist size, the less
likely to develop hypertension. South African Whites were shown to ingest a greater
amount of sodium than Africans and still maintain a lower blood pressure (Charlton et.
al., 2005). This suggests that a healthier diet (White vs. urban Africans) can withstand a
greater intake of salt. The South Indian population inversely correlates to the South
African White population, i.e. an excessive salt intake in Whites results in a lower
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prevalence of hypertension as compared to the South Indians where a reduced salt intake
results in a higher prevalence of hypertension.
The next reason for a small White sample size could be socio-economic. The supremacy
stigma attached to the White population during apartheid still lingers. Whites were said
to be more superior hence high up on the hierarchy. Due to their superiority, they are
accustomed to better living conditions which attributes to a stronger immune system due
to proper sanitation and good nutrition. The wealth attached to supremacy allows private
health care (Kothari and Mehta, 1984) where education about proper diet is available
(Charlton et. al., 2005). White patients are therefore rarely found in public health care
facilities and as a consequence little access is made to them.
Although an association with hypertension was not detected in this White population,
HLA-DR4 was shown to be associated with hypertensive Brazilian Caucasians (Gerbase-
DeLima et. al., 1992).
Part B of this study aimed to find associations between HLA and glomerulonephritides.
The initial glomerular diseases selected were IgAN, MGN and FSGS but due to
inadequate numbers, IgAN, MGN and FSGS had to be grouped as glomerulonephritides
together with other NS diseases. This may present a bias as there is a vast array of
glomerular diseases hence patients with specific diseases may present with specific HLA
antigens.
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HLA profiles differ between race and geographic location but studies have also aimed to
prove associations between the severity of renal disease and the race of a population.
FSGS has been on the increase globally (Balakrishnan et al., 2003; Bhimma et. al., 2006;
Sorof et. al., 1998) and has also replaced MGN as being the most common cause of NS
(Pontier and Patel, 1994; Sorof et. al., 1998; Swaminathan et. al., 2006).
FSGS has been shown to be more common in Black populations compared to White and
Hispanic populations (Bonilla-Felix et. al., 1990) although Dragovic et. al. (2005)
showed no difference between the increase of hypertension in Blacks, Whites and
Hispanics. In addition FSGS is more common in males than females (Korbet et. al.,
1996). This setting showed a similar increase of FSGS in Black African and Indian
children with a trend towards the male sex (Bhimma et. al., 2006). Similarly, clinical
data from this study shows a comparable prevalence of FSGS between Indians and
Africans. Authors have suggested that the increase of FSGS is due to factors other than
race (Swaminathan et. al., 2006). Although a study failed to show any HLA associations
with FSGS (Freedman et. al., 1994b) there has been a confirmed association with HLA
antigens (Gerbase-DeLima et. al., 1998).
The present study showed a significant association with HLA-A33 and
glomerulonephritides in the Indian adult population with a relative risk of 4.4. This
denotes that Indians carrying the HLA-A33 antigen are 4.4 more likely to develop
glomerulonephritides than those not bearing the allele. The HLA-A locus alleles are
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Class I alleles. These results challenge other studies where Class II HLA associations
were identified.
HLA-DR3 was shown to be associated with NS in German Caucasian children (Ruder et.
al., 1990) and with Idiopathic MN in an English (Klouda et. al., 1979) as well as an
American population together with HLA DR5 (Freedman et. al., 1994a).
Alfiler et. al. (1980) showed an association between HLA-DRw7 and Steroid-responsive
NS in Australian Caucasian children. The Class II HLA-DR4 allele has been shown to be
associated with Idiopathic FSGS patients from a Brazilian White population (Gerbase-
DeLima et. al., 1998) as well as a Polish population (Krasowska-Kwiecien et. al., 2001).
In this setting the Class II HLA DQB1*0603 has been shown to be associated with
HBVMN in the African pediatric population (Bhimma et. al., 2002). Interestingly Class I
associations were found in this setting. HLA-Bw44 was shown to be associated with
MCNS in the Indian population and HLA-B w21 with MN in the African pediatric
population (Adhikari et. al., 1985).
A Race combined analysis has been carried out in an American setting with significant
associations (Freedman et. al., 1994b). This study showed positive associations between
HLA-A74, HLA-A33, HLA-A68 and HLA-DR11 and Race-combined
glomerulonephritides patients however when corrected for P, no significance was
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maintained. This suggests that Race plays a role in determining susceptibility to
glomerulonephritides in KZN.
Although IgAN is the leading cause of GN (Swaminathan et. al., 2006) it is a disease that
is uncommon in the African race although GN accounts for 25% of the African renal
population (Seedat et. al., 1984). Seedat et. al. (1988) found 2 cases of IgAN in an
African population of 252 patients in KZN and Jennette and colleagues (1985) reported 6
cases out of a total of 461 African American patients. A study with the greatest recorded
sample size of African IgAN patients (Crowley-Nowick et. al., 1991) revealed the
following: 1) African IgAN patients progress to ESRD at the same pace as White patients
with a similar clinical course and 2) The IgA2 (A2m(1) and A2m(2)) allotypes do not
serve as markers for or protect the African race from IgAN.
IgAN is also uncommon in this African population. The clinical data reveal only 3
patients with IgAN from an excess of 500 patients. Unfortunately due to lack of follow
up samples were not collected from these patients. Follow up is very important as IgAN
patients are suggested to be a high risk group (Freedman et. al., 1994b). Since the IgA
immune system was unable to clarify reasons for the African population being protected
from IgAN (Crowley-Nowick et. al., 1991), I decided to explore the 11LA complex genes
for a possible reason.
HLA-A30, HLA-A29, HLA-A34, HLA-B70, HLA-1358, HLA-B42 and HLA-DR11 were
shown to be extremely significantly higher in the African population when compared to
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the Indian and White populations. These results correspond to Assounga et. al. (2007,
Congress Abstract) who also showed a marked increase of HLA-A30 and HLA-B58 in
African patients when compared to White and Indian populations. In White Americans
HLA-B27 and HLA-DR1 occur in linkage disequilibrium. The susceptibility of Whites
to IgAN is suggested to stem directly or from extended haplotypes of HLA-B27 and
HLA-DR1 (Freedman et. al., 1994b). This triggers the converse question as to whether
HLA-A30 and HLA-B58 in linkage in this environment serve as protective loci for
Africans against [gAN but further in depth studies are required to aim to prove that
phenomenon. Also HLA-A33 was shown to be represented by the White and Indian
populations but absent in the African population. This deficiency may suggest that HLA-
A33 is a possible protective allele.
It is also interesting to note that although IgAN is common in the White population
(Swaminathan et. al., 2006), only three cases were found in this patient population but
this could be due to White patients attending private health care facilities. Seedat et. al.
(1984) showed analgesic nephropathy to be the most common cause of ESRD in KZN
White patients compared to GN and hypertension. Due to the small sample size of White
patients, this study was intended to expand into the Pietermaritzburg region where White
patients are said to be common. However attempts made to approach the hospital
(Grey's) were unfruitful.
HLA association studies with IgAN have been performed in various settings. A study by
Li et. al. (1991) showed an association between HLA-DQw7 and IgAN in Caucasians.
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Doxiadis et. al. (2001) showed HLA-B35 to be increased in IgAN patients on the
transplant list. It is interesting to note that race was not mentioned so it cannot be
concluded if this association was race determined. Freedman et. al. (1994b) reported
positive (HLA-1327 and HLA-DRI) as well as negative (HLA-DR2) HLA associations
with IgAN proposing that HLA-B27 and HLA-DR1 are disease susceptible alleles and
HLA-DR2 is a protective allele. Alternatively, Fennessy et. al. (1996) and Huang et. al.
(1989) noted no association with HLA.
HLA differs between race and geographic locations. In the Japanese population, IgA
nephropathy has been shown to be associated with HLA-DQw4 (Hiki et. al., 1991) and
has more than once been shown to be associated with HLA-DR4 (Hiki et. al., 1982; Hiki
et. al., 1990; Kashiwabara et. al., 1982; Kohara et. al., 1985; Nomoto et. al., 1984)
directly or otherwise. Interestingly Fauchet et. al. (1980) showed an association of HLA-
DR4 with IgAN.
Furthermore alleles of the central MHC (D6S273*133 and D6S273*131) have been
shown to be strongly associated with the levels of IgA suggesting a possible
predisposition to IgAN as IgA deficiency (IgAD) patients lacked central MHC alleles
present in patients with IgAN (Matthews et. al., 2002).
Unfortunately this study could not provide any associations with IgAN due to the small
sample size. IgAN is common in KZN Indians and by increasing the sample size in
future studies, significance might be obtained.
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Although members of the African race group are said to reach ESRD more rapidly than
any other race group, they rarely tend to donate kidneys. This is postulated to be
associated with traditional beliefs. The donor list comprised of 67 African donors
compared to 187 Indian and 230 White donors. This presents a great difficulty as HLA
profiles are unique to populations and HLA matching is important in transplantation due
to graft rejection. Assounga et al. (2007, Congress Abstract) suggests each population
group should contribute equally to the donor pool to improve the donor/recipient
matching.
The following limitations were presented by the study.
1) HLA compatibility is of utmost importance in organ transplant as it determines graft
rejection. The donor and recipient therefore need to have a close HLA match. Since the
donor population on the transplant register was used as the control population a bias
might be presented. This study therefore needs to be extended to a wider control
population.
2) This study may not reflect the total distribution of HLA types in the KZN populations
as the transplant registry is not complete. According to the South African Department of
Health website (http://www.doh.gov.za ), this is due to lack of funds.
3) Due to the presumptive diagnosis of hypertension in patients, this study needs to be
conducted in a population where the diagnosis of hypertension is known to be due to
renal diseases.
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4) This study involved HLA associations with glomerulonephritdes. Due to the extensive
classification of glomerular diseases, HLA molecules in patients with these diseases may
present different antigens. Therefore future studies should involve specific classifications
(i.e. groups of patients with identical biopsy proven diseases).
4) This study presented challenges in the face of statistical analysis as a very small
sample size has a few HLA antigens as opposed to the extensive array of alleles from a
great population. It therefore becomes difficult to compare individual alleles with a large
control population. An increase in sample size is therefore warranted.
5) HLA typing is very expensive therefore using it as a method of screening would be
impractical in a poor setting. Therefore funding should be allocated for screening tests in
provincial hospitals. The way forward would be to encourage the government to
prioritize and provide resources for renal disease for although the kidney is the most
precious vital organ it is often taken for granted.
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CONCLUSION
In summary, HLA-B40 is a possible disease susceptibility marker for Hypertension in
KZN Indian renal patients. Consistent with other studies HLA-1315 is shown to be
associated with Hypertension in African KZN renal patients. White hypertensives are
few hence no association was found with HLA. IgAN has been shown to be very rare in
Africans in KZN. This is in accordance with other investigations. A possible linkage
between HLA-A30 and HLA-B58 in this setting could be responsible for IgAN being
uncommon among Africans but further studies are required. Glomerulonephritides is
associated with HLA-A33 in the KZN Indian population with no associations among the
African and White populations.
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A PPENDIX
Dilutions for DNA to a concentration of 15ng/u1 were done as follows using a DNA
sample with a concentration of 95.3ng/ul.
15




= 53.3 ul H2O
7.9 ul DNA with a concentration of 95.3ng/u1 + 53.3  H2O nuclease-free H2O gives a
concentration of 15ng/u1 DNA.
95.3
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